LPA inhibitors and uses thereof

By designing and using LPA-specific RNA interferers, the problem of difficulty in reducing LPA expression levels in the prior art is solved, significant inhibition of Apo(a) protein and mRNA expression is achieved, and new treatment of cardiovascular diseases and strokes is provided. Potential approach.

CN116801886BActive Publication Date: 2024-12-06CHENGDU XINZHENGHE PHARMACEUTICAL TECHNOLOGYCO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202280008865.5
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2022-01-20
Filing Date
2022-09-19
Publication Date
2024-12-06
Estimated Expiration
2042-09-19

AI Technical Summary

Technical Problem

The prior art is difficult to effectively reduce the expression level of lipoprotein (a) [Lp(a)], which is an independent risk factor for cardiovascular disease and stroke, and existing treatments are limited.

Method used

Develop an LPA RNA interfering agent (LPARNAi agent) to selectively inhibit the expression of LPA genes through RNA interfering agents designed for specific nucleotide sequences, including the design and synthesis of RNAi with oligonucleotide sequences that are complementary to LPA genes. and improve its delivery efficiency by targeting ligands.

Benefits of technology

In vitro and in vivo experiments, the expression of Apo(a) protein and its mRNA can be significantly inhibited, up to 99% knockdown efficiency, effectively reducing the expression level of LPA, and potentially used to prevent and treat LPA-related diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN116801886B_ABST
    Figure CN116801886B_ABST
Patent Text Reader

Abstract

An LPA RNA interference (RNAi) agent comprising nucleotides targeting a nucleic acid molecule encoding LPA (apo(a)), wherein the oligonucleotide comprises at least 12 consecutive nucleotides of any one of the nucleotide sequences of SEQ ID NO: 2 to SEQ ID NO: 92. Pharmaceutical compositions comprising one or more RNA interference agents, and in vivo delivery of the RNA interference agents to liver cells provide inhibition of LPA gene expression and use of such nucleic acid-based therapeutic agents to reduce circulating levels of lipoprotein (a) (Lp(a)) and treat or prevent cardiovascular-related diseases.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Cross-references

[0002] This application claims priority to Chinese Patent Application No. 202111110773.1, filed on September 18, 2021, entitled LPA inhibitors and uses thereof, and Chinese Patent Application No. 202210068123.3, filed on January 20, 2022, entitled siRNA conjugates and uses thereof, which are incorporated herein by reference in their entirety. Technical Field

[0003] The present application relates to the field of biomedicine technology, and specifically to an LPA inhibitor and its use. Background Art

[0004] RNA interference (RNAi) refers to the phenomenon of highly conserved, double-stranded RNA (dsRNA)-induced, highly efficient and specific degradation of homologous mRNA in the process of evolution. Since RNAi technology can be used to specifically eliminate or shut down the expression of specific genes (dsRNA with a length of more than thirty will cause interferon toxicity), this technology has been widely used to explore gene function and the treatment of infectious diseases and malignant tumors. Short dsRNA guides gene-specific post-transcriptional silencing in many organisms including vertebrates, which has become a tool that can be used to study gene function. RNAi is mediated by the RNA-induced silencing complex (RISC), which is a complex formed by siRNA, Argonaute protein and Dicer enzyme. Among them, the small dsRNA intermediate molecule, i.e., small RNA double strands, is first cut by the Dicer enzyme to obtain small dsRNA intermediate molecules, i.e., small RNA double strands, and then these small RNA double strands are first unwound to form "functional" single strands, thereby playing a "guide" role for the RISC complex. For each small dsRNA molecule, only one strand, i.e., the guide strand, can bind to a specific Argonaute protein to form an activated RISC complex. RNA interfering agents such as siRNA and microRNA are oligonucleotides that inhibit the gene translation of proteins by gene silencing, ie, by causing the degradation of mRNA molecules to prevent the formation of proteins.

[0005] Lipoprotein(a) [Lp(a)] is a heterogeneous low-density lipoprotein (LDL)-like particle that contains a lipid core and apolipoprotein B (apoB-100), and a unique component, apolipoprotein(a) (apo(a)) attached to apoB-100 by a disulfide bond.

[0006] The LPA (Apo(a)) gene is primarily expressed in the liver, and expression is restricted to humans and non-human primates. Lp(a) levels in humans are genetically defined and do not change significantly with diet, exercise, or other lifestyle changes. The length of LPA varies depending on the number of Kringle KIV2 domains present, and its expression is inversely correlated with the number of domains present.

[0007] Analysis of Lp(a) levels in multiple studies suggests that high Lp(a) levels are an independent risk factor for cardiovascular disease, stroke, and other related conditions, including atherosclerotic stenosis. In addition, genome-wide association studies have also implicated LPA as a genetic risk factor for diseases such as atherosclerotic stenosis. Therefore, there is a need to develop therapeutic agents that can be associated with LPA-related diseases, especially pharmaceutical preparations that reduce LPA expression levels. Summary of the invention

[0008] One of the purposes of the present application is to provide an LPA RNAi agent and method capable of regulating (e.g., reducing) the level of LPA (apo (a)) in cells, subjects, such as mammals (e.g., humans). LPA is the name of the gene encoding apolipoprotein (a) (apo (a)), a key component of lipoprotein (a) particles (Lp (a)). The human DNA sequence (SEQ ID NO. 1) is as follows Figure 1a and Figure 1b LPA (also known as apo (a)) RNA interference (RNAi) agents (also known as RNAi triggers or triggers) and compositions containing LPA RNAi agents are used to selectively and effectively inhibit the expression of LPA genes.

[0009] Another object of the present application is to provide a pharmaceutical composition comprising the LPA RNAi agent.

[0010] Another object of the present application is to provide the use of the LPA RNAi agent for preventing or treating a disease or condition or for preparing a drug for preventing or treating a disease or condition.

[0011] In a first aspect, the present application provides an LPA RNA interference (RNAi) agent comprising a first nucleotide sequence, wherein the first nucleotide sequence includes at least 12 consecutive nucleotides of any one of SEQ ID NO:2 to SEQ ID NO:183 or a nucleotide sequence complementary thereto, or a sequence that differs from the at least 12 consecutive nucleotides by no more than 3 nucleotides, and the nucleotides are in a modified or unmodified state.

[0012] Preferably, the first nucleotide sequence consists of 12 to 30 nucleotides, preferably 19 to 23 nucleotides.

[0013] Preferably, the first nucleotide sequence is a single-stranded oligonucleotide or a double-stranded nucleotide.

[0014] Preferably, one or more nucleotides in the first nucleotide sequence are modified to form modified nucleotides.

[0015] Preferably, the first nucleotide sequence comprises any one of the modified positive chain nucleotide sequences listed in Table 2 or a sequence that differs therefrom by no more than 3 nucleotides.

[0016] Preferably, the first nucleotide sequence is a sense strand or an antisense strand.

[0017] Preferably, the first nucleotide sequence comprises a double-stranded structure of an antisense strand and a sense strand.

[0018] Preferably, the sense strand and / or antisense strand independently comprises one or more modified nucleotides.

[0019] Preferably, the modified nucleotide is at least one of 2'-fluoro modified nucleotide, 2'-O-methyl modified nucleotide, 2'-O-methoxyethyl modified nucleotide, 2'-O-alkyl modified nucleotide, 2'-O-allyl modified nucleotide, bicyclic nucleic acid, deoxyribonucleotide, EVP, UNA and GNA.

[0020] Preferably, at least one of the 2nd, 5th, 6th, 8th, 10th, 14th and 16th positions at the 5' end of the antisense strand is modified with a 2'-fluorine-modified nucleotide, and preferably 5-7 of the positions are modified with a 2'-fluorine-modified nucleotide.

[0021] Preferably, the sense strand and / or antisense strand independently comprises one or more phosphorothioate bonds; preferably, the sense strand comprises two consecutive phosphorothioate bonds between the terminal nucleotides at the 3' and 5' ends, or the antisense strand comprises two consecutive phosphorothioate bonds between the terminal nucleotides at the 3' and 5' ends.

[0022] In certain embodiments, the antisense strand comprises any one of the modified antisense strand nucleotide sequences in Table 2 or a sequence that differs therefrom by no more than 3 nucleotides.

[0023] Further preferably, the sense strand and antisense strand have the following characteristics: (1) the sense strand comprises or consists of the modified sense strand sequence listed in Table 2, and the antisense strand comprises or consists of the modified antisense strand sequence listed in Table 2

[0024] Preferably, the RNA interference agent further comprises a ligand.

[0025] Preferably, the ligand comprises a targeting group.

[0026] Preferably, the targeting group comprises an asialoglycoprotein receptor ligand.

[0027] Preferably, the asialoglycoprotein receptor ligand comprises a galactose cluster.

[0028] Preferably, the ligand is used for conjugation to the sense strand and / or antisense strand, preferably, for conjugation to the sense strand.

[0029] In one embodiment, the LPA RNA interference agent comprises the following structure:

[0030] ZX(I),

[0031] Wherein X is a nucleotide sequence, and Z is the first linker portion of the nucleotide sequence, wherein Z and X can be directly connected or connected through a chemical group, and the general formula of Z is as shown in (Z-1), wherein one end of the O group is connected to the nucleotide sequence:

[0032]

[0033] wherein R1 is O, S, NR3 or CR3R4, wherein R3 and R4 are each independently hydrogen, halogen, substituted or unsubstituted aliphatic, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted heterocyclic or substituted or unsubstituted cycloalkyl;

[0034] Wherein R2 is -O-, -S-, -NH-, -CH2-, -C(O)-, -OC(O)-, -C(O)O-, -NHC(O)-, -C(O)NH-, -CH2NH-, -CH2O-, -NH-C(O)-CH2-, -C(O)-CH2-NH-, or -NH(CO)NH-, wherein the -CH2- may be optionally substituted by a substituent selected from halogen, alkyl, alkoxy and alkylamino; and a1 and a2 are the same or different and are each selected from an integer of 0 to 20, preferably an integer of 1 to 10.

[0035] Preferably, the nucleotide sequence represented by X is the above-mentioned first nucleotide sequence.

[0036] Preferably, the first linker moiety Z is connected to the second linker moiety L1, and the second linker moiety L1 is connected to the branch point group E.

[0037] Preferably, the branch point group E is connected to a targeting assembly, wherein a is an integer selected from 0 to 10, preferably an integer from 1 to 5; wherein the targeting assembly comprises the tethering part L2 and the targeting part T in a ratio of 1:1.

[0038] Specifically, the LPA RNA interfering agent structural formula can be expressed as:

[0039]

[0040] In one embodiment, the LPA RNA interference agent has the following structure:

[0041]

[0042] In the general formula (II):

[0043] L3 includes a third linker portion, and L4 is a targeting portion. Specifically, L3 and L4 may be the same or different. Preferably, L3 and L4 are respectively the following structures:

[0044]

[0045] X is a nucleotide sequence, which can be a sense strand or an antisense strand,

[0046] Y is O or S,

[0047] Wherein b, c, d and e are selected from integers from 0 to 10, respectively, and b and e are not simultaneously 0. In one embodiment, b is 0, and e is an integer from 3 to 6.

[0048] On the other hand, the present application also provides the use of the aforementioned LPA RNA interfering agent in the preparation of a drug for reducing LPA mRNA or protein expression in mammals, or for preventing and / or treating related diseases or conditions, or reducing the risk of diseases or conditions.

[0049] In certain embodiments, the related disease or disorder refers to an expression level of LPA protein of 100 nmol / L or above.

[0050] In certain embodiments, the disease or condition comprises a hepatopathic disease.

[0051] In certain embodiments, the disease or condition comprises an inflammatory, cardiovascular or metabolic disease.

[0052] In certain embodiments, the cardiovascular and cerebrovascular diseases include hyperlipidemia, stroke, atherosclerosis, thrombosis, coronary heart disease or aortic valve stenosis.

[0053] In certain embodiments, the drug comprises a pharmaceutically acceptable excipient, preferably, the pharmaceutically acceptable excipient is PBS buffer or physiological saline.

[0054] In certain embodiments, the medicament is a composition further comprising at least one of an LDL-C, cholesterol, and triglyceride lowering agent.

[0055] In certain embodiments, the drug is a composition that also includes a PCSK9 RNAi inhibitor, a PCSK9 antibody inhibitor, and a PCSK9 small molecule inhibitor.

[0056] On the other hand, the present application provides a method for reducing the expression of LPA mRNA or protein in cells or tissues, comprising: contacting the cells or tissues with an effective amount of the aforementioned LPA RNAi agent or the aforementioned pharmaceutical composition.

[0057] In certain embodiments, the cell is a hepatocyte.

[0058] In certain embodiments, wherein the tissue is liver tissue.

[0059] In certain embodiments, the cells and tissues are ex vivo.

[0060] In certain embodiments, the cells and tissues are located in a subject.

[0061] On the other hand, the present application provides a method for reducing the expression of LPA mRNA or protein in a subject, comprising: administering an effective amount of the aforementioned LPA RNAi agent or the aforementioned pharmaceutical composition to a subject in need thereof.

[0062] In another aspect, the present application provides a method for preventing or treating a disease or disorder, comprising administering an effective amount of the aforementioned LPA RNAi agent or the aforementioned pharmaceutical composition to a target subject.

[0063] In certain embodiments, the compound or the pharmaceutical composition is administered to the subject subcutaneously, intravenously, orally, rectally, or intraperitoneally.

[0064] Beneficial effects: Experiments have shown that the LPARNAi agent of the present application can significantly inhibit the expression of Apo(a) protein and the corresponding mRNA in both in vitro and in vivo experiments (in mice). In the mouse experiment, the expression of Apo(a) protein can be knocked down by up to 99% at high doses. BRIEF DESCRIPTION OF THE DRAWINGS

[0065] Figure 1a-1b It is the specific sequence of SEQ ID NO.1.

[0066] Figure 2 These are the experimental results of Example 7 of the present invention.

[0067] Figure 3 These are the experimental results of Example 8 of the present invention.

[0068] Figure 4 These are the experimental results of Example 9 of the present invention.

[0069] Figure 5 These are the experimental results of Example 10 of the present invention.

[0070] Figure 6 These are the experimental results of Example 11 of the present invention. DETAILED DESCRIPTION

[0071] In order to make the technical problems, technical solutions and beneficial effects to be solved by the present invention more clearly understood, the present invention is further described in detail below in conjunction with the accompanying drawings, embodiments and chemical reaction formulas. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not intended to limit the present invention.

[0072] Definition of terms

[0073] In this application, the terms "LPA", "Apo(a)" or "apo(a)" are used interchangeably and generally refer to any nucleic acid or protein sequence encoding apo(a). For example, in certain embodiments, apo(a) includes a DNA sequence encoding apo(a), an RNA sequence transcribed from a DNA encoding apo(a) (including genomic DNA containing introns and exons), an mRNA sequence encoding apo(a), or a peptide sequence of apo(a).

[0074] In this application, the term "apo(a) specific inhibitor" refers to any agent that can specifically inhibit the expression of apo(a) nucleic acids and / or apo(a) proteins. For example, apo(a) specific inhibitors include nucleic acids (including antisense oligonucleotides), peptides, antibodies, small molecules and other agents that can inhibit the expression of apo(a) nucleic acids and / or apo(a) proteins. In certain embodiments, by specifically regulating apo(a) nucleic acid expression and / or apo(a) protein expression, apo(a) specific inhibitors can affect other components of the lipid transport system, including downstream components. Similarly, in certain embodiments, apo(a) specific inhibitors can affect other molecular processes in animals.

[0075] In this application, the terms "nucleic acid" and "polynucleotide" are used interchangeably and refer to a polymeric form of nucleotides (deoxyribonucleotides or ribonucleotides or analogs thereof) of any length, which can be double-stranded and single-stranded molecules. The following are non-limiting examples of polynucleotides: genes or gene fragments (e.g., probes, primers, EST or SAGE tags), exons, introns, messenger RNA (mRNA), transfer RNA, ribosomal RNA, ribozymes, cDNA, recombinant polynucleotides, branched polynucleotides, plasmids, vectors, isolated DNA of any sequence, isolated RNA of any sequence, nucleic acid probes, siRNA, miRNA, shRNA, RNAi agents and primers. Polynucleotides can be modified or substituted with any of various modifications or substitutions known in the art at one or more bases, sugars and / or phosphates. Polynucleotides can include modified nucleotides, such as methylated nucleotides and nucleotide analogs. In addition, the nucleotide structure can be modified before or after polymer assembly. Polynucleotides can be modified after polymerization, such as by coupling with a labeling component. Unless otherwise specified or required, any embodiment herein that is a polynucleotide encompasses the double-stranded form and each of the two complementary single-stranded forms known or predicted to comprise the double-stranded form.

[0076] In this application, "target nucleic acid" or "target sequence" generally refers to a nucleic acid molecule to which an antisense compound is intended to hybridize to produce a desired effect (e.g., antisense activity). Exemplary antisense compounds include antisense oligonucleotides, which have sufficient complementarity with their target nucleic acid to allow hybridization under physiological conditions. In certain embodiments, "target nucleic acid" includes, but is not limited to, DNA or RNA encoding mammalian LPA, such as human LPA mRNA.

[0077] In the present application, the term "oligonucleotide" generally refers to a polymer composed of a plurality of nucleotide residues (deoxyribonucleotides or ribonucleotides, or its related structural variants or synthetic analogs) connected by a phosphodiester bond (or its related structural variants or synthetic analogs). Therefore, although the term "oligonucleotide" generally refers to a naturally occurring nucleotide polymer in which the nucleotide residues and the connection therebetween are naturally occurring, it should be understood that the scope of the term also includes various analogs, including but not limited to: peptide nucleic acid (PNA), phosphoramidate, phosphorothioate, methylphosphonate, 2-O-methyl ribonucleic acid, etc. The exact size of the molecule can depend on specific applications. Oligonucleotides are generally shorter in length, usually about 10-30 nucleotide residues, but the term can also refer to molecules of any length, although the terms "polynucleotide" or "nucleic acid" are generally used for larger oligonucleotides.

[0078] In certain embodiments, the oligonucleotide comprises one or more unmodified ribonucleosides (RNA) and / or unmodified deoxyribonucleosides (DNA) and / or one or more modified nucleosides. The term "modified oligonucleotide" generally refers to an oligonucleotide comprising at least one modified nucleoside and / or at least one modified internucleoside linkage.

[0079] In the present application, the term "modified nucleoside" generally means a nucleoside comprising at least one chemical modification compared to a naturally occurring RNA or DNA nucleoside. The modified nucleoside comprises a modified sugar moiety and / or a modified nucleobase.

[0080] In the present application, the term "nucleobase" generally refers to a heterocyclic pyrimidine or purine compound, which is a component of all nucleic acids and includes adenine (A), guanine (G), cytosine (C), thymine (T) and uracil (U). Nucleotides may include modified nucleotides or nucleotide mimetics, abasic sites (Ab or X) or substitute substitutions. As used in the present application, "nucleobase sequence" generally refers to the order of consecutive nucleobases that are independent of any sugar, linkage or nucleobase modification. The term "unmodified nucleobase" or "naturally occurring nucleobase" generally refers to naturally occurring heterocyclic nucleobases of RNA or DNA: purine bases adenine (A) and guanine (G); and pyrimidine bases thymine (T), cytosine (C) (including 5-methyl C) and uracil (U). "Modified nucleobase" generally refers to any nucleobase that is not a naturally occurring nucleobase.

[0081] In this application, the term "sugar moiety" generally refers to the naturally occurring sugar moiety or modified sugar moiety of a nucleoside. The term "naturally occurring sugar moiety" generally refers to the ribofuranosyl group as found in naturally occurring RNA or the deoxyribofuranosyl group as found in naturally occurring DNA. "Modified sugar moiety" means a substituted sugar moiety or sugar surrogate.

[0082] In this application, the term "internucleoside linkage" generally means a covalent linkage between adjacent nucleosides in an oligonucleotide. A "naturally occurring internucleoside linkage" means a 3' to 5' phosphodiester linkage. A "modified internucleoside linkage" means any internucleoside linkage other than a naturally occurring internucleoside linkage.

[0083] In the present application, the term "antisense oligonucleotide" refers to a single-stranded oligonucleotide molecule having a nucleobase sequence complementary to a corresponding fragment of a target nucleic acid (e.g., a target genomic sequence, an mRNA precursor, or an mRNA molecule). In certain embodiments, the antisense oligonucleotide is 12 to 30 nucleobases in length. In certain embodiments, the antisense oligonucleotide is an unmodified or modified nucleic acid having a nucleotide sequence complementary to a target nucleic acid (e.g., an LPA polynucleotide) sequence.

[0084] In the present application, the term "antisense strand" generally refers to a strand of an RNAi agent (e.g., dsRNA) that includes a region that is substantially complementary to a target sequence. When used herein, the term "complementarity region" generally refers to a region that is substantially complementary to a sequence (e.g., a target sequence) defined in the present application on the antisense strand. When the complementary region is not completely complementary to the target sequence, the mispairing may be in the interior or terminal region of the molecule. Typically, the most tolerated mispairing is in the terminal region, for example, within 5, 4, 3, or 2 nucleotides at the 5' end and / or 3' end.

[0085] In the present application, the term "sense strand" (S) generally refers to a strand of an RNAi agent, comprising a region substantially complementary to the region of the antisense strand as defined herein. A "sense" strand is sometimes referred to as a "sense" strand. With their sequence, the antisense strand targets the desired mRNA, while the sense strand targets different targets. Therefore, if the antisense strand is incorporated into RISC, the correct target is targeted. The incorporation of the sense strand can result in off-target effects. These off-target effects can be limited by using modifications or using 5' end caps on the sense strand.

[0086] In the present application, the term "complementary" refers to the ability of an oligonucleotide or polynucleotide comprising a first nucleotide sequence (such as an RNAi agent sense strand or LPA mRNA) to hybridize (form base pair hydrogen bonds) and form a duplex or double helix structure with an oligonucleotide or polynucleotide comprising a second nucleotide sequence under certain conditions when used to describe a first nucleotide sequence (such as an RNAi agent antisense strand). Complementary sequences include Watson-Crick base pairs or non-Watson-Crick base pairs, and include natural or modified nucleotides or nucleotide mimetics, as long as the above requirements for their hybridization ability are achieved. "Complementary" does not necessarily have core base complementarity on each nucleoside. On the contrary, some mispairings can be tolerated.

[0087] In the present application, the term "completely complementary" generally means that all (100%) bases in the continuous sequence of the first polynucleotide will hybridize with the same number of bases in the continuous sequence of the second polynucleotide. The continuous sequence may contain all or part of the first or second nucleotide sequence. As used in the present application, "partially complementary" generally means that in the base sequence pairs of hybridization, at least about 70% of the bases in the continuous sequence of the first polynucleotide will hybridize with the same number of bases in the continuous sequence of the second polynucleotide. As used in the present application, "substantially complementary" generally means that in the base sequence pairs of hybridization, at least about 90% of the bases in the continuous sequence of the first polynucleotide will hybridize with the same number of bases in the continuous sequence of the second polynucleotide. As used in the present application, the terms "complementary", "completely complementary" and "substantially complementary" can be used in terms of base matching between the sense strand and antisense strand of the RNAi agent or between the antisense strand of the RNAi agent and the sequence of the LPA mRNA. Sequence identity or complementarity does not depend on modification. For the purposes of determining identity or complementarity, for example, A and Af are complementary to U (or T) and identical to A.

[0088] In this application, the term "ligand" generally refers to any compound or molecule that can be covalently or otherwise chemically bound to a biologically active substance (such as an oligonucleotide). In certain embodiments, a ligand can interact directly or indirectly with another compound such as a receptor, and the receptor that interacts with the ligand can be present on the cell surface, or alternatively can be an intracellular and / or intercellular receptor, and the interaction of the ligand with the receptor can result in a biochemical reaction, or can be simply a physical interaction or combination.

[0089] In this application, the terms "induce", "inhibit", "enhance", "elevate", "increase", "reduce", "lower" and the like generally refer to a quantitative difference between two states. For example, "an amount effective to inhibit the activity or expression of apo(a)" means that the level of activity or expression of apo(a) in the treated sample will be lower than the level of activity or expression of apo(a) in the untreated sample. The terms apply, for example, to expression levels and activity levels. The terms "reduce" and "reduce" are used interchangeably and generally refer to any change that is less than the original. "Reduce" and "reduce" are relative terms and require comparison between before and after measurement. "Reduce" and "reduce" include complete depletion.

[0090] In certain embodiments, the term "reduction" can be detected by standard methods known in the art (such as those described in the present application), and the expression level / amount of a gene, gene product, such as a protein or a biomarker in a first sample is compared to the expression level / amount of a corresponding gene, gene product, such as a protein or a biomarker in a second sample by about 5% to 95%, or 100% overall reduction. In certain embodiments, the term "reduction" refers to the reduction in the expression level / amount of a gene or biomarker in a test sample, wherein the reduction refers to at least about 0.9 times to 0.01 times the expression level / amount of the corresponding gene or biomarker.

[0091] In the present application, the term "expression" generally refers to the process by which a gene ultimately produces a protein. Expression includes, but is not limited to, transcription, post-transcriptional modification (eg, splicing, polyadenylation, addition of a 5'-cap), and translation.

[0092] In the present application, the term "pharmaceutically acceptable" generally refers to one or more non-toxic substances that do not interfere with the effectiveness of the biological activity of the active ingredient. Such preparations may generally contain salts, excipients, buffers, preservatives, compatible carriers and optional other therapeutic agents. When used in medicine, the salt should be a pharmaceutically acceptable salt, but non-pharmaceutically acceptable salts can be conveniently used to prepare pharmaceutically acceptable salts, and they cannot be excluded from the scope of this application. Such pharmacologically and pharmaceutically acceptable salts include salts prepared from the following acids: hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, maleic acid, acetic acid, salicylic acid, citric acid, boric acid, formic acid, malonic acid, succinic acid, etc. Pharmaceutically acceptable salts can also be prepared as alkali metal salts or alkaline earth metal salts, such as sodium salts, potassium salts or calcium salts.

[0093] In the present application, the term "prevention and / or treatment" includes not only prevention and / or treatment of diseases, but also generally includes prevention of the onset of diseases, slowing or reversing the progression of diseases, preventing or slowing the onset of one or more symptoms associated with diseases, reducing and / or alleviating one or more symptoms associated with diseases, reducing the severity and / or duration of diseases and / or any symptoms associated therewith, and / or preventing further increase in the severity of diseases and / or any symptoms associated therewith, preventing, reducing or reversing any physiological damage caused by diseases, and any pharmacological effects that are generally beneficial to patients being treated. The RNAi agent or pharmaceutical composition of the present application does not need to achieve complete cure or eradication of any symptoms or manifestations of diseases to form a viable therapeutic agent. As recognized in the relevant art, drugs used as therapeutic agents can reduce the severity of a given disease state, but do not need to eliminate every manifestation of the disease to be considered a useful therapeutic agent. Similarly, prophylactically administered treatments constitute viable preventive agents that do not need to completely and effectively prevent the onset of symptoms. It is sufficient to simply reduce the impact of the disease in the subject (e.g., by reducing the number or severity of its symptoms, or by increasing the effectiveness of another treatment, or by producing another beneficial effect), or reduce the likelihood of disease occurrence or exacerbation.

[0094] In this application, the terms "disease" or "disorder" are used interchangeably and generally refer to any deviation of a subject from a normal state, such as any change in the state of the body or certain organs that prevents or disturbs the performance of functions, and / or causes symptoms such as discomfort, dysfunction, pain or even death in the person suffering from the disease or contacting it. Disease or disorder may also be referred to as distemper, discomfort, ailment, malady, disorder, sickness, illness, complaint, inderdisposion or affectation.

[0095] In the present application, the term "administering" generally refers to introducing the present application's pharmaceutical preparation into a subject's body by any introduction or delivery route. Any method known to those skilled in the art for contacting cells, organs or tissues with the drug can be used. The administration may include, but is not limited to, intravenous, intraarterial, intranasal, intraperitoneal, intramuscular, subcutaneous or oral administration. The daily dose may be divided into one, two or more dosages of suitable form to be administered at one, two or more times during a certain time period.

[0096] In the present application, the term "contact" generally refers to two or more different types of substances being contacted together in any order, in any manner, and for any duration. Contact may occur in vivo, ex vivo, or in vitro. In some embodiments, it may refer to making the RNAi agent or composition of the present application directly contact cells or tissues. In other embodiments, the term refers to making the RNAi agent or composition of the present application indirectly contact cells or tissues. For example, the method of the present application includes a method in which a subject contacts the RNAi agent or composition of the present application, and then the RNAi agent or composition contacts cells or tissues by diffusion or any other active transport or passive transport process known in the art (compounds circulate in the body through the process).

[0097] In the present application, the term "effective amount" or "effective dose" generally refers to an amount sufficient to achieve or at least partially achieve the desired effect. A "therapeutically effective amount" or "therapeutically effective dose" of a drug or therapeutic agent is generally any amount of a drug that promotes disease regression (which is demonstrated by the reduction of disease symptom severity, the increase in the frequency and duration of the disease asymptomatic period, or the prevention of damage or disability caused by suffering from the disease) when used alone or in combination with another therapeutic agent. A "preventive effective amount" or "preventive effective dose" of a drug generally refers to an amount of a drug that inhibits the development or recurrence of a disease when administered alone or in combination with another therapeutic agent to a subject at risk of disease development or disease recurrence. In certain embodiments, an "effective amount" refers to the amount of an RNAi agent that produces an expected pharmacological, therapeutic or preventive result.

[0098] In this application, the term "subject" generally refers to a human or non-human animal (including mammals) in need of diagnosis, prognosis, improvement, prevention and / or treatment of a disease, such as humans, non-human primates (apes, gibbons, gorillas, chimpanzees, orangutans, macaques), livestock (dogs and cats), farm animals (horses, cattle, goats, sheep, pigs) and experimental animals (mice, rats, rabbits, guinea pigs). Human subjects include fetuses, newborns, infants, adolescents and adult subjects. Subjects include animal disease models.

[0099] In this application, the terms "includes," "comprising," "having," "may," "containing," and variations thereof are generally intended to be open transitional phrases, terms, or words that do not exclude the possibility of additional actions or structures. The term "consisting of" generally indicates that no other components (or, similarly, features, integers, steps, etc.) can be present. Nouns of indefinite number also include plural referents unless the context clearly dictates otherwise.

[0100] When the term "about" is used in reference to a numerical range, a cutoff or a specific value is used to indicate that the stated value may vary from the recited value by up to 10%. Thus, the term "about" can be used to encompass variations of ±10% or less, ±5% or less, ±1% or less, ±0.5% or less, or ±0.1% or less from a specific value.

[0101] LPA RNAi Agents

[0102] The RNAi agent for inhibiting the expression of the LPA gene described in the present application (referred to as LPA RNAi agent in the present application) is delivered to cells expressing the LPA gene, and inhibits or knocks down the expression of LPA in vitro and / or in vivo through the biological process of RNA interference (RNAi). As used in the present application, unless otherwise specifically indicated, LPA may refer to the LPA gene, LPA mRNA or LP (a) protein under appropriate circumstances. RNAi agents include, but are not limited to, short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro RNA (miRNA) and short hairpin RNA (shRNA).

[0103] On the one hand, the present application provides an LPA RNAi agent, which may include an oligonucleotide targeting a nucleic acid molecule encoding LPA (apo (a)), wherein the oligonucleotide comprises at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22 or at least 23 consecutive nucleotides in any one of the nucleotide sequences of SEQ ID NO: 2 to SEQ ID NO: 183. The nucleotide sequence may be in a modified state (and a ligand added after modification) and in an original state without modification.

[0104] In certain embodiments, the oligonucleotide consists of 12 to 30 nucleotides. For example, the length of the oligonucleotide can be 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 22, 23, 24, 25, 26, 27, 28, 29 or 30 nucleotides long. For another example, the length of the oligonucleotide can be 17, 18, 19, 20, 21, 22, 23, 24, 25 or 26 nucleotides long.

[0105] In certain embodiments, the oligonucleotide comprises a nucleotide sequence selected from the following sequences: any one of SEQ ID NO: 2 to SEQ ID NO: 183 or a sequence that differs therefrom by no more than 3 nucleotides. For example, when the nucleotide sequence is different from any one of SEQ ID NO: 2 to SEQ ID NO: 183, a maximum of one, two or three nucleotide substitutions (e.g., adenosine is substituted by uracil), deletions or additions occur, the derived RNAi agent can still have reduced inhibitory activity, compared to the nucleotide sequence shown in any one of SEQ ID NO: 2 to SEQ ID NO: 183 from which the derivative is derived, the inhibitory effect is not less than 20%.

[0106] In certain embodiments, the oligonucleotide is a single-stranded oligonucleotide or a double-stranded oligonucleotide.

[0107] For example, the oligonucleotide may be an antisense oligonucleotide. For another example, the oligonucleotide may be siRNA.

[0108] For example, the oligonucleotide may comprise only an antisense strand. For another example, the oligonucleotide may comprise a sense strand and an antisense strand.

[0109] In certain embodiments, the length of the sense strand and antisense strand of the LPA RNAi agent is independently 17 to 30 nucleotides long. In certain embodiments, the sense strand and antisense strand are independently 17 to 26 nucleotides long. In certain embodiments, the sense strand and antisense strand are 19-26 nucleotides long. In certain embodiments, the sense strand and antisense strand of the RNAi agent are independently 17, 18, 19, 20, 21, 22, 23, 24, 25 or 26 nucleotides long. The sense strand and antisense strand may be the same length or they may be different lengths. In certain embodiments, the sense strand and antisense strand are each 26 nucleotides long. In certain embodiments, the sense strand is 23 nucleotides long and the antisense strand is 21 nucleotides long. In certain embodiments, the sense strand is 22 nucleotides long and the antisense strand is 21 nucleotides long. In certain embodiments, the sense strand is 21 nucleotides long and the antisense strand is 21 nucleotides long. In certain embodiments, the sense strand is 21 nucleotides long and the antisense strand is 21 nucleotides long. In certain embodiments, the sense strand is 19 nucleotides long and the antisense strand is 21 nucleotides long.

[0110] In certain embodiments, the antisense strand sequence is 100% (perfect) complementary or at least 90% (substantially) complementary to a nucleotide sequence present in LPAmRNA (sometimes referred to as a target sequence). The sense strand sequence is 100% (perfect) complementary or at least 90% (substantially) complementary to a sequence in the antisense strand, and thus the sense strand sequence is perfectly identical or at least 90% identical to a nucleotide sequence present in LPAmRNA (target sequence).

[0111] In certain embodiments, the sense strand and antisense strand of the LPARNAi agent are annealed to form a duplex. The sense strand and antisense strand of the LPARNAi agent are partially, substantially or completely complementary to each other. In the complementary duplex region, the sense strand core sequence is at least 90% complementary or 100% complementary to the antisense core sequence. In certain embodiments, the sense strand core sequence contains at least 17, at least 18, at least 19, at least 20 or at least 21 nucleotide sequences that are at least 90% or 100% complementary to the corresponding 17, 18, 19, 20 or 21 nucleotide sequences of the antisense strand core sequence (i.e., the sense strand and antisense core sequence of the LPARNAi agent have at least 90% base pairing or 100% base pairing of at least 17, at least 18, at least 19, at least 20 or at least 21 nucleotide regions).

[0112] In certain embodiments, the sense strand and / or antisense strand may optionally and independently contain additional 1, 2, 3, 4, 5 or 6 nucleotides (extensions) at the 3' end, 5' end or both 3' and 5' ends of the core sequence. If there are additional nucleotides in the antisense strand, it may be complementary to or not complementary to the corresponding sequence in the LPA mRNA. If there are additional nucleotides in the sense strand, it may be identical or not identical to the corresponding sequence in the LPA mRNA. If there are additional nucleotides in the antisense strand, it may be complementary or not complementary to the additional nucleotides of the corresponding sense strand.

[0113] In certain embodiments, the LPA RNAi agent comprises an antisense strand having a 3' extension of 1, 2, 3, 4, 5 or 6 nucleotides in length. In other embodiments, the LPA RNAi agent comprises an antisense strand having a 3' extension of 1, 2 or 3 nucleotides in length. In certain embodiments, one or more antisense strand extension nucleotides include uracil or thymidine nucleotides or nucleotides complementary to the corresponding LPA RNA sequence.

[0114] In certain embodiments, the LPA RNAi agent comprises an antisense strand having a 5' extension of 1, 2, 3, 4 or 5 nucleotides in length. In other embodiments, the LPA RNAi agent comprises an antisense strand having a 5' extension of 1 or 2 nucleotides in length. In certain embodiments, one or more antisense strand extension nucleotides include uracil or thymidine nucleotides or nucleotides complementary to the corresponding LPA mRNA sequence. The antisense strand may have any of the above-mentioned 3' extensions and any of the described 5' antisense strand extensions in combination.

[0115] In certain embodiments, the LPA RNAi agent comprises a sense strand having a 3' extension of 1, 2, 3, 4 or 5 nucleotides in length. In certain embodiments, one or more sense strand extension nucleotides include adenosine, uracil or thymidine nucleotides, AT dinucleotides or nucleotides corresponding to nucleotides in the LPA RNA sequence.

[0116] In certain embodiments, the LPA RNAi agent comprises a sense strand having a 5' extension of 1, 2, 3, 4, 5 or 6 nucleotides in length. In certain embodiments, one or more sense strand extension nucleotides comprise uracil or adenosine nucleotides or nucleotides corresponding to nucleotides in the LPA RNA sequence. The sense strand may have a 3' extension and / or a 5' extension.

[0117] In certain embodiments, the antisense strand comprises the following nucleotide sequence: any one of SEQ ID NO: 2 to SEQ ID NO: 92 or a sequence that differs therefrom by no more than 3 nucleotides.

[0118] In certain embodiments, the sense strand comprises the following nucleotide sequence: any one of SEQ ID NOs: 93-183 or a sequence that differs therefrom by no more than 3 nucleotides.

[0119] In certain embodiments, the antisense strand and sense strand sequences of the LPA RNAi agent are as shown in Table 1.

[0120] The LPA RNAi agents described herein can be formed by annealing the antisense strand to the sense strand. A sense strand containing the sequences listed in Table 1 can be hybridized with any antisense strand as long as the two sequences have at least 90% complementarity over a continuous sequence of 16, 17, 18, 19, 20 or 21 nucleotides.

[0121] In certain embodiments, the LPA RNAi agent antisense strand comprises a nucleotide sequence of any antisense strand sequence in Table 1. In certain embodiments, the LPA RNAi agent antisense strand comprises a sequence of nucleotides 1-17, 2-17, 1-18, 2-18, 1-19, 2-19, 1-20, 2-20, 1-21, 2-21, 1-22, 2-22, 3-22, 1-23, 2-23, 3-23, or 4-23 of any antisense strand sequence in Table 1. In certain embodiments, the LPA RNAi agent sense strand comprises a nucleotide sequence of any sense strand sequence in Table 1. In certain embodiments, the LPA RNAi agent sense strand comprises a sequence of nucleotides 1-17, 2-17, 1-18, 2-18, 1-19, 2-19, 1-20, 2-20, 1-21, or 2-21 of any sense sequence in Table 1.

[0122] In certain embodiments, the sense strand and antisense strand of the LPARNAi agent described in the present application contain the same number of nucleotides. In certain embodiments, the sense strand and antisense strand of the LPARNAi agent described in the present application contain different numbers of nucleotides. In certain embodiments, the sense strand 5' end of the LPARNAi agent and the antisense strand 3' end form a flat end. In certain embodiments, the sense strand 3' end of the LPARNAi agent and the antisense strand 5' end form a flat end. In certain embodiments, both ends of the RNAi agent form a flat end. In certain embodiments, neither end of the LPARNAi agent is a flat end. As used in the present application, a flat end refers to the end of a double-stranded RNAi agent in which the terminal nucleotides of the two annealed strands are complementary (forming complementary base pairs). In certain embodiments, the sense strand 5' end of the LPARNAi agent and the antisense strand 3' end form a scattered end. In certain embodiments, the sense strand 3' end of the RNAi agent and the antisense strand 5' end form a scattered end. In certain embodiments, both ends of the LPARNAi agent form a scattered end. In certain embodiments, both ends of the LPA RNAi agent are not scattered ends. As used in the present application, scattered ends generally refer to the ends of double-stranded RNAi agents in which the terminal nucleotides of the two annealed chains form a pair (i.e., do not form an overhang) but are not complementary (i.e., form a non-complementary pair). In the present application, an overhang is a segment of one or more unpaired nucleotides at the end of one chain of a double-stranded RNAi agent. Unpaired nucleotides can be on the sense strand or the antisense strand, thereby producing a 3' or 5' overhang. In certain embodiments, the LPA RNAi agent contains: a flat end and a scattered end, a flat end and a 5' overhang end, a flat end and a 3' overhang end, a scattered end and a 5' overhang end, a scattered end and a 3' overhang end, two 5' overhang ends, two 3' overhang ends, 5' overhang ends and 3' overhang ends, two scattered ends or two flat ends.

[0123] In certain embodiments, the LPA RNAi agent is prepared as a salt, a mixed salt, or a free acid.

[0124] Modified nucleotides

[0125] The LPA RNAi agents of the present application include unmodified nucleic acids and nucleic acids modified to improve efficacy, and polymers of nucleoside substitutes. Unmodified nucleic acids refer to those in which the sugar, base and phosphate structure components are the same or substantially the same as the natural components, preferably the natural components in the human body. The prior art regards rare or unusual but naturally occurring RNAs as modified RNAs, see Limbach et al., (1994) Nucleic Acids Res. 22: 2183-2196. Such rare or unusual modified RNAs are generally referred to as modified RNAs (obviously because they are the result of post-transcriptional modifications) and are classified as unmodified RNAs in the present application. The modified RNA used in the present application refers to those in which the components of the nucleic acid, i.e., one or more components of the sugar, base and phosphate structure, are different from the natural components, preferably different from the natural components produced from the human body. Nucleoside surrogates are molecules in which the ribose phosphate backbone is replaced by a non-ribose phosphate configuration that places the bases in the correct spatial relationship for hybridization substantially similar to that seen with the ribose phosphate backbone, e.g., an uncharged analog of the ribose phosphate backbone.

[0126] In certain embodiments, an LPA RNAi agent contains one or more modified nucleotides.

[0127] In certain embodiments, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or 100% of the nucleotides in the LPA RNAi agent are modified.

[0128] In certain embodiments, the sense strand and / or antisense strand independently comprises one or more modified nucleotides.

[0129] The two main purposes of modifying RNAi agents are to obtain their stability against degradation in the biological environment and to improve pharmacological properties, such as pharmacodynamic properties. RNAi agents can include non-natural bases, or non-natural sugars, such as non-sugar compound annular carrier molecules, typical properties of non-natural sugars for RNAi agents. RNAi agents can include bonds between nucleotides (e.g., chiral thiophosphate bonds) to increase nuclease resistance. RNAi agents can also include, or optionally include, ribose analogs to increase nuclease resistance.

[0130] Modified nucleotides include, but are not limited to, deoxynucleotides, nucleotide mimetics, abasic nucleotides (denoted herein as X, Ab), 2'-modified nucleotides, 3' to 3'-linked (inverted) nucleotides (denoted herein as invdN, invN, invn, invX, invAb, nucleotides containing non-natural bases, bridged nucleotides, peptide nucleic acids (PNA), 2', 3'-broken nucleotide mimetics (unlocked nucleobase analogs, denoted herein as NUNA or NUNA), locked nucleotides (denoted herein as NLNA or NLNA), 3'-O-methoxy (2' internucleoside linked) nucleotides (denoted herein as 3'-OMen), 2'-F-arabino nucleotides (denoted herein as NfANA or NfANA), 5'-Me, 2'-fluoro nucleotides (denoted herein as NfANA or NfANA), The 2'-modified nucleotides (i.e., nucleotides having a group other than a hydroxyl group at the 2' position of the five-membered sugar ring) include, but are not limited to, 2'-O-methyl nucleotides (represented as lowercase n in the nucleotide sequence in the present application), 2'-deoxy-2'-fluoro nucleotides (represented as Nf in the present application, and also represented as 2'-fluoro nucleotides in the present application), 2'-deoxy nucleotides (represented as dN in the present application), 2'-methoxyethyl (2'-O-2-methoxyethyl) nucleotides (represented as NM or 2'-MOE in the present application), 2'-amino nucleotides and 2'-alkyl nucleotides. Specifically, in a single LPA More than one modification may be incorporated into an RNAi agent or even into a single nucleotide thereof. The LPA RNAi agent sense and antisense strands may be synthesized and / or modified by methods known in the art. Modification at one nucleotide is independent of modification at another nucleotide.

[0131] Modified nucleotides also include nucleotides with modified bases. Modified bases include, but are not limited to, synthetic and natural bases, 5-substituted pyrimidines, 6-azapyrimidines, and N-2, N-6, and O-6 substituted purines, including 2-aminopropyladenine, 5-propynyluracil and 5-propynylcytosine, 5-methylcytosine (5-me-C), 5-hydroxymethylcytosine, xanthine, 2-propyl and other alkyl derivatives of adenine and guanine, 2-thiothymine and 2-thiocytosine, 5-halogenated uracil and cytosine, 5-propynyl uracil and cytosine, 6-azo uracil, cytosine and thymine, 8-halogenated, 8-amino, 8-thiol, 8-sulfanyl, 8-hydroxy and other 8-substituted adenines and guanines, 5-halogenated, especially 5-bromo, 5-trifluoromethyl and other 5-substituted uracil and cytosines, 7-methylguanine and 7-methyladenine, 8-azaguanine and 8-azaadenine.

[0132] In certain embodiments, one or more nucleotides of the LPA RNAi agent are linked by a non-standard linkage or backbone (ie, a modified internucleoside linkage or a modified backbone). In certain embodiments, the modified internucleoside linkage is a non-phosphate-containing covalent internucleoside linkage. Modified internucleoside linkages or backbones include 5'-phosphorothioate groups (denoted herein as a lowercase s before a nucleotide, such as in sN, sn, sNf, or sdN) with normal 3'-5' linkages, chiral phosphorothioates, thiophosphates, phosphorodithioates, phosphotriesters, aminoalkyl-phosphotriesters, methyl phosphonates and other alkyl esters including 3'-alkylene phosphonates and chiral phosphonates, phosphinates, phosphoramidates including 3'-aminophosphoramidates and aminoalkylphosphoramidates, thiocarbonylphosphoramidates, thiocarbonylalkyl-phosphonates, thiocarbonylalkylphosphotriesters, morpholino linkages, and boranophosphates; 2'-5' linked analogs of these, and those with reversed polarity in which adjacent pairs of nucleoside units are linked 3'-5' to 5'-3' or 2'-5' to 5'-2'. In other embodiments, the modified internucleoside linkage or backbone has no phosphorus atom. The modified internucleoside linkage without phosphorus atom includes but is not limited to short chain alkyl or cycloalkyl sugar intra-linkage, mixed heteroatoms and alkyl or cycloalkyl sugar intra-linkage, one or more short chain heteroatoms or heterocyclic sugar intra-linkage. In certain embodiments, the modified internucleoside backbone includes but is not limited to siloxane backbone, sulfide, sulfoxide and sulfone backbone; formacetyl and thioformyl backbone, methyleneformyl and thioformyl backbone, olefin-containing backbone, aminosulfonate backbone, methyleneimino and methylenehydrazine backbone, sulfonate and sulfonamide backbone, amide backbone; and others with mixed N, O, S and CH2 component parts.

[0133] Ligand

[0134] In certain embodiments, the LPA RNAi agent further comprises a ligand.

[0135] In certain embodiments, the ligand changes the distribution, targeting or lifespan of the RNAi agent to which it is bound. In certain embodiments, the ligand enhances the affinity of the selected target compared to the species lacking the ligand. The selected target is, for example, a molecule, a cell or a cell class and a cavity such as a cell or organ cavity, a tissue, an organ or a region of the body.

[0136] In certain embodiments, the ligand is capable of promoting the properties of transport, hybridization and specificity, and is capable of promoting nuclease resistance of the resulting natural or modified oligoribonucleotide, or promoting nuclease resistance of a polymer molecule containing any of the monomers and / or natural or modified ribonucleotide combinations described in this application.

[0137] For example, the ligand can also include a targeting group, for example, a cell or tissue targeting agent, such as a lectin, a glycoprotein, a lipid or a protein, such as an antibody that binds to a specific cell such as a hepatocyte or a jejunal cell. The targeting group can be thyrotropin, melanocyte stimulating hormone, a lectin, a glycoprotein, surfactant protein A, a mucin carbohydrate, a multivalent lactose, a multivalent galactose, N-acetylgalactosamine, N-acetylglucosamine, a multivalent mannose, a multivalent trehalose, a glycosylated polyamino acid, a multivalent galactose, an iron transfer protein, a bisphosphonate, a polyglutamate, a polyaspartate, a lipid, a cholesterol, a steroid, a bile acid, a folic acid, a vitamin B12 or a biotin.

[0138] In certain embodiments, the ligand comprises a targeting group.

[0139] In certain embodiments, the targeting group can be monovalent, divalent, trivalent, tetravalent or have a higher valency. Representative targeting groups include compounds with affinity for cell surface molecules, cell receptor ligands, haptens, antibodies, monoclonal antibodies, antibody fragments, and antibody mimics with affinity for somatic cell surface molecules.

[0140] In certain embodiments, the targeting group is capable of targeting hepatocytes or the liver.

[0141] In certain embodiments, the targeting group comprises an asialoglycoprotein receptor ligand.

[0142] In certain embodiments, the asialoglycoprotein receptor ligand comprises one or more galactose derivatives or galactose clusters or is composed of one or more galactose derivatives or galactose clusters. In the present application, the term galactose derivatives includes galactose, and galactose derivatives with an affinity for the asialoglycoprotein receptor (equal to or greater than the affinity of galactose). Galactose derivatives include: galactose, galactosamine, N-formylgalactosamine, N-acetyl-galactosamine, N-propionyl-galactosamine, N-n-butyryl-galactosamine and N-iso-butyrylgalactosamine. Galactose derivatives have been used to target molecules to hepatocytes in vivo by binding to the asialoglycoprotein receptor (ASGPr) on the surface of hepatocytes. The combination of ASGPr ligands with ASGPr promotes cell-specific targeting to hepatocytes and endocytosis of molecules into hepatocytes. The galactose cluster can be attached to the 3' or 5' end of the RNAi polynucleotide using methods known in the art.

[0143] In certain embodiments, the ligand is conjugated to the sense strand and / or antisense strand. For example, the ligand can be conjugated to the 5' end and / or 3' end of the sense strand and / or antisense strand.

[0144] Delivery vehicle

[0145] In certain embodiments, a delivery vehicle can be used to deliver an LPA RNAi agent to a cell or tissue. A delivery vehicle is a compound that improves the delivery of an LPA RNAi agent to a cell or tissue. A delivery vehicle may include or consist of a polymer, such as an amphiphilic polymer, a reversibly modified polymer or peptide, or a reversibly modified membrane active polyamine.

[0146] In certain embodiments, LPA RNAi agents can be combined with lipids, nanoparticles, polymers, liposomes, micelles or other delivery systems available in the art. LPA RNAi agents can also be chemically conjugated to targeting groups, lipids (including cholesterol and cholesterol-based derivatives), nanoparticles, polymers or other delivery systems available in the art.

[0147] The present application describes a method for delivering LPA RNAi agents to mammalian hepatocytes in vivo. In certain embodiments, a delivery vehicle can be used. The delivery vehicle can be, but is not limited to, a polymer (such as an amphiphilic polymer, a membrane active polymer), a ligand, etc. In certain embodiments, the LPA RNAi agent is connected to a targeting ligand comprising an asialoglycoprotein ligand. For example, the LPA RNAi agent can be connected to a targeting ligand comprising or consisting of a galactose cluster.

[0148] As mentioned above, the present application provides a siRNA conjugate, the general formula of which is as follows:

[0149]

[0150] (I-0) or

[0151]

[0152] In the general formula (I):

[0153] X is a nucleotide sequence, which may be the sense strand or antisense strand of siRNA, and Z is the first linker portion of the nucleotide sequence, wherein Z and X may be directly connected or connected via a chemical group, and the general formula of Z is as shown in (Z-1), wherein one end of the O group is connected to the nucleotide sequence:

[0154]

[0155] wherein R1 is O, S, NR3 or CR3R4, wherein R3 and R4 are each independently hydrogen, halogen, substituted or unsubstituted aliphatic, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted heterocyclic or substituted or unsubstituted cycloalkyl;

[0156] Wherein R2 is -O-, -S-, -NH-, -CH2-, -C(O)-, -OC(O)-, -C(O)O-, -NHC(O)-, -C(O)NH-, -CH2NH-, -CH2O-, -NH-C(O)-CH2-, -C(O)-CH2-NH-, or -NH(CO)NH-, wherein the -CH2- may be optionally substituted by a substituent selected from halogen, alkyl, alkoxy and alkylamino; and a1 and a2 are the same or different and are respectively selected from integers of 0 to 20, preferably integers of 1 to 10, and more preferably integers of 1 to 5.

[0157] Preferably, the nucleotide sequence represented by X is the above-mentioned first nucleotide sequence.

[0158] Preferably, the first linker moiety Z is connected to the second linker moiety L1, and the second linker moiety L1 is connected to the branch point group E.

[0159] Preferably, the branch point group E is connected to a targeting assembly, wherein a is an integer selected from 0 to 10, preferably an integer from 1 to 5; wherein the targeting assembly comprises the tethering part L2 and the targeting part T in a ratio of 1:1.

[0160] In the general formula (II):

[0161] L3 includes a third linker portion, and L4 is a targeting portion. Specifically, T in the general formula (I) and L3 and L4 in the general formula (II) may be the same or different. Preferably, L3 and L4 are respectively the following structures:

[0162]

[0163] X is a nucleotide sequence, which can be a sense strand or an antisense strand,

[0164] Y is O or S,

[0165] Wherein b, c, d and e are selected from integers from 0 to 10, respectively, and b and e are not simultaneously 0. In one embodiment, b is 0, and e is an integer from 3 to 6.

[0166] In another aspect of the present invention, the second joint portion L1 has the following structure:

[0167]

[0168] or

[0169] wherein f, g, h and i are integers from 1 to 20, preferably integers from 1 to 10, respectively.

[0170] In one embodiment, the position of L1 in the ligand is shown in the box structure below:

[0171]

[0172] In another aspect of the present invention, the tethered portion L2 has the following structural formula:

[0173]

[0174] wherein j, k, l, m, n and o are integers from 1 to 20, preferably integers from 1 to 10, respectively.

[0175] Specifically, the position of L2 in the ligand is shown in the box structure below:

[0176]

[0177] Another aspect of the present invention provides an LPA RNA interference agent, comprising: a sense strand and an antisense strand, and the above-mentioned siRNA conjugate.

[0178] Another object of an embodiment of the present invention is to provide a composition comprising the above-mentioned RNA interference agent.

[0179] The siRNA conjugate provided in the embodiment of the present invention can improve the efficiency of the targeting part binding to cells or cell receptors, and increase the effect of RNA interference.

[0180] In a preferred embodiment, the general formula of compound Z in the targeting ligand is as shown below (Z-2):

[0181]

[0182] Preferably R2 is -NH-, in which case the compound Z is:

[0183]

[0184] Preferably R2 is -C(O)-, in which case compound Z is

[0185]

[0186] Preferably, L1 is the following structure:

[0187] or

[0188]

[0189] In one embodiment, in the general formula (I), the compound E is selected from one of the following five structures:

[0190] In one embodiment, the compound L2 in the general formula (I) is

[0191]

[0192] Where j, k, l, m, n and o are integers from 1 to 20 respectively;

[0193] Preferably, L2 has the following structural formula:

[0194]

[0195] or

[0196]

[0197] In a preferred embodiment, the targeting ligand of formula (I) (excluding the X moiety) has the following structure:

[0198]

[0199]

[0200]

[0201] In one embodiment, T in the targeting ligand is selected from one of N-acetyl-galactosamine, galactose, galactosamine, N-formyl-galactosamine, N-propionyl-galactosamine, N-n-butyryl-galactosamine and N-isobutyryl-galactosamine, preferably N-acetyl-galactosamine, and the structural formula is as follows:

[0202]

[0203] In a preferred embodiment, the targeting ligand in the general formula (I) is linked to the end of the siRNA via a phosphate group, a phosphorothioate group or a phosphonic acid group.

[0204] In a preferred embodiment, the targeting ligand has the following structure:

[0205]

[0206]

[0207]

[0208]

[0209]

[0210] In one embodiment of the general formula (II), H—O—L3 in the targeting ligand is:

[0211]

[0212] wherein R2 is independently -O-, -S-, -NH-, -CH2-, -C(O)-, -OC(O)-, -C(O)O-, -NHC(O)-, -C(O)NH-, -CH2NH-, -CH2O-, -NH-C(O)-CH2-, -C(O)-CH2-NH-, -NH(CO)NH-, wherein the -CH2- may be optionally substituted by halogen or alkyl, wherein the alkyl may be optionally further substituted by a substituent selected from hydroxy, amino, halogen, alkoxy and alkylamino);

[0213] The p, q, r, s, t and u are independently selected from integers of 0 to 20, preferably integers of 1 to 10.

[0214] In a preferred embodiment, H—O—L3 has the following structure:

[0215]

[0216]

[0217] In another preferred embodiment of the general formula (II), H—O—L4 in the targeting ligand is:

[0218] In a preferred embodiment, H—O—L4 has the following structure:

[0219]

[0220]

[0221] In a preferred embodiment, the general formula (II) has the following structure:

[0222]

[0223]

[0224]

[0225]

[0226]

[0227] Wherein Y is O or S.

[0228] In another preferred embodiment, the siRNA conjugate has the following structure:

[0229]

[0230]

[0231]

[0232]

[0233]

[0234]

[0235] Wherein Y is O or S.

[0236] On the other hand, the above structures bound to the 3' end can all be bound to the 5' end of X.

[0237] Pharmaceutical Composition Examples

[0238] On the other hand, the present application provides a pharmaceutical composition comprising the aforementioned LPA RNAi agent and optionally a pharmaceutically acceptable excipient.

[0239] In certain embodiments, the LPA RNAi agent can be used to inhibit the expression of LPA in cells, cell groups or tissues such as in a subject. In certain embodiments, the LPA RNAi agent is used to prepare a composition for administration to a subject, i.e., a pharmaceutical composition or a drug. For example, a pharmaceutical composition or a drug may include a pharmacologically effective amount of at least one of the LPA RNAi agents and one or more pharmaceutically acceptable excipients. A pharmaceutically acceptable excipient (excipient) is a substance other than an active pharmaceutical ingredient (API, therapeutic product, such as an LPA RNAi agent) that has been appropriately evaluated for safety and is intentionally included in a drug delivery system. The excipient does not play or is not intended to play a therapeutic effect at a predetermined dose. Excipients can be used to a) assist in the processing of a drug delivery system during manufacture, b) protect, support or enhance the stability, bioavailability or patient acceptability of an API, c) assist in product identification and / or d) enhance any other properties of the overall safety and effectiveness of delivering an API during storage or use. A pharmaceutically acceptable excipient may or may not be an inert substance.

[0240] Excipients include: absorption enhancers, anti-adherents, anti-foaming agents, antioxidants, binders, binders, buffers, carriers, coatings, pigments, delivery enhancers, delivery polymers, dextran, dextrose, diluents, disintegrants, emulsifiers, extenders, fillers, flavoring agents, glidants, humectants, lubricants, oils, polymers, preservatives, saline, salts, solvents, sugars, suspending agents, sustained release matrices, sweeteners, thickeners, tonicity agents, vehicles, hydrophobic agents, and wetting agents.

[0241] The pharmaceutical composition may contain other additional components commonly found in pharmaceutical compositions. Such additional components include, but are not limited to, antipruritic agents, astringents, local anesthetics, or anti-inflammatory agents (such as antihistamines, diphenhydramine, etc.). It is also contemplated that cells, tissues, or isolated organs expressing or comprising RNAi agents defined herein can be used as "pharmaceutical compositions".

[0242] In certain embodiments, the LPA RNAi agent is combined with one or more additional therapeutic agents or treatments, including but not limited to: small molecule drugs, antibodies, antibody fragments and / or vaccines. The RNAi agent and the pharmaceutical composition comprising the LPA RNAi agent disclosed herein can be packaged or included in a kit, container, package or dispenser. The LPA RNAi agent and the pharmaceutical composition comprising the LPA RNAi agent can be packaged in a prefilled syringe or vial.

[0243] The pharmaceutical composition of the present application can be used to inhibit the expression of LPA genes in cells, tissues or organisms. In certain embodiments, the pharmaceutical composition is used to treat subjects suffering from diseases, illnesses or conditions that will benefit from reduced or inhibited LPA expression. In certain embodiments, the pharmaceutical composition is used to treat subjects at risk of developing diseases, illnesses or conditions that will benefit from reduced or inhibited LPA expression. Diseases, illnesses or conditions that will benefit from reduced or inhibited LPA expression include, but are not limited to: Buerger's disease, peripheral artery disease, coronary artery disease, metabolic syndrome, acute coronary syndrome, aortic stenosis, aortic regurgitation, aortic dissection, retinal artery occlusion, cerebrovascular disease, mesenteric ischemia, superior mesenteric artery occlusion, renal artery stenosis, stable / unstable angina, acute coronary syndrome, heterozygous or homozygous familial hypercholesterolemia, hyperlipoprotein betalipoproteinemia, cerebrovascular atherosclerosis, cerebrovascular disease and venous thrombosis. In certain embodiments, the subject is a mammal, including but not limited to humans.

[0244] Consider comprising at least one LPA RNAi agent described herein, cell, tissue and non-human organism. Prepare the cell, tissue or non-human organism by delivering the LPA RNAi agent to the cell, tissue or non-human organism in any manner available in the art. In certain embodiments, the cell is a mammalian cell, including but not limited to human cells. The cell, tissue or non-human organism can be used for research or as a research tool (such as drug testing or diagnosis).

[0245] use

[0246] On the other hand, the present application provides use of the aforementioned LPA RNAi agent or the aforementioned pharmaceutical composition in the preparation of a medicament for preventing and / or treating a disease or condition, or reducing the risk of a disease or condition.

[0247] In certain embodiments, the disease or condition includes a disease or condition associated with an elevated level of Lp(a)-containing particles. In this application, the term "Lp(a)" generally refers to LDL-like particles comprising apo(a) and apoB. Apo(a) is linked to apoB via a disulfide bond.

[0248] In certain embodiments, the disease or condition comprises a hepatopathic disease.

[0249] In certain embodiments, the disease or condition comprises an inflammatory, cardiovascular or metabolic disease.

[0250] In this application, the term "metabolic disease or condition" generally refers to a condition characterized by a change or disturbance in metabolic function. "Metabolic" and "metabolism" are terms well known in the art and generally include a full range of biochemical processes occurring in a living organism. Metabolic disorders include, but are not limited to, dyslipidemia caused by hyperglycemia, prediabetes, diabetes (type 1 and type 2), obesity, insulin resistance, metabolic syndrome, and type 2 diabetes.

[0251] In this application, the term "inflammatory disease or condition" refers to a disease, disease state, syndrome or other condition that results in inflammation. For example, rheumatoid arthritis and liver fibrosis are inflammatory conditions. Other examples of inflammatory conditions include sepsis, myocardial ischemia / reperfusion injury, adult respiratory distress syndrome, nephritis, transplant rejection, inflammatory bowel disease, multiple sclerosis, arteriosclerosis, atherosclerosis and vasculitis.

[0252] In the present application, the term "symptoms of cardiovascular and cerebrovascular diseases or disorders" generally refers to phenomena caused by and accompanying cardiovascular and cerebrovascular diseases or disorders, and serves as an indicator of cardiovascular and cerebrovascular diseases or disorders.

[0253] In another aspect, the present application provides a method for preventing and / or treating a disease or disorder, comprising administering to a target subject an effective amount of the aforementioned LPA RNAi agent and / or the aforementioned pharmaceutical composition.

[0254] In certain embodiments, the LPA RNAi agent described herein can be used to treat diseases or conditions that benefit from reducing LPA expression. Examples of the disease or condition include, but are not limited to, Buerger's disease, peripheral artery disease, coronary artery disease, metabolic syndrome, acute coronary syndrome, aortic stenosis, aortic regurgitation, aortic dissection, retinal artery occlusion, cerebrovascular disease, mesenteric ischemia, superior mesenteric artery occlusion, renal artery stenosis, stable / unstable angina, acute coronary syndrome, heterozygous or homozygous familial hypercholesterolemia, hyperlipoprotein betalipoproteinemia, cerebrovascular atherosclerosis, cerebrovascular disease, and venous thrombosis. In certain embodiments, the method includes administering a composition, such as a pharmaceutical composition comprising the LPA RNAi agent described herein to a target mammal.

[0255] In certain embodiments, a therapeutically effective amount of one or more of the described LPA RNAi agents is administered to a subject, thereby inhibiting the expression of LPA in the subject (eg, an amount effective to inhibit the expression of LPA in the subject).

[0256] In certain embodiments, the method further comprises the step of administering a second therapeutic agent or treatment. In certain embodiments, the second therapeutic agent is another LPA RNAi agent (e.g., an LPA RNAi agent targeting a different sequence within the LPA target). In other embodiments, the second therapeutic agent can be selected from: small molecule drugs, antibodies, antibody fragments, and vaccines.

[0257] The administration route is the approach that RNAi agent contacts with the body. Generally, the administration method of medicine and nucleic acid for treating the subject is well known in the art, and can be applied to the administration of the composition described in the present application. The compound described in the present application can be administered in a preparation appropriately customized for a particular approach via any suitable approach. Therefore, the compound described in the present application can be administered by injection, such as intravenous, intramuscular, intradermal, subcutaneous or intraperitoneal.

[0258] In certain embodiments, oligonucleotide delivery techniques known in the art can be used to deliver LPA RNAi agents or compositions described herein to cells, cell groups, tissues or subjects. Generally, any suitable method recognized in the art for delivering nucleic acid molecules (in vitro or in vivo) can be applied to LPA RNAi agents described herein. For example, delivery can be by local administration (local administration) (such as direct injection, implantation or topical administration (topical administration), systemic administration, or subcutaneous, intravenous, oral, intraperitoneal or parenteral routes, including intracranial (such as intraventricular, intraparenchymal and intrathecal), intramuscular, transdermal, airway (aerosol), nasal, rectal or local (including buccal and sublingual) administration. In certain embodiments, the composition is administered by subcutaneous or intravenous infusion or injection.

[0259] In certain embodiments, LPA RNAi agents can be combined with lipids, nanoparticles, polymers, liposomes, micelles or other delivery systems available in the art. RNAi agents can also be chemically conjugated to targeting groups, lipids (including but not limited to cholesterol and cholesterol-based derivatives), nanoparticles, polymers, liposomes, micelles or other delivery systems available in the art. LPA RNAi agents can be conjugated to delivery polymers. In certain embodiments, delivery polymers are reversibly masked / modified amphiphilic membrane-active polyamines.

[0260] Inhibition of expression

[0261] On the other hand, the present application provides a method for reducing the expression of LPA mRNA or protein in cells or tissues, comprising: contacting the cells or tissues with an effective amount of the aforementioned LPA RNAi agent or the aforementioned pharmaceutical composition.

[0262] In certain embodiments, wherein the cell is a hepatocyte.In certain embodiments, wherein the tissue is liver tissue.

[0263] In certain embodiments, the cells and tissues are ex vivo. In other embodiments, the cells and tissues are in vivo.

[0264] On the other hand, the present application provides a method for reducing the expression of LPA mRNA or protein in a subject, comprising: administering an effective amount of the aforementioned LPA RNAi agent or the aforementioned pharmaceutical composition to the target subject.

[0265] As used herein, the terms "silencing", "reducing", "inhibiting", "downregulating" or "knocking down gene expression" when referring to the LPA gene mean that when a cell, cell population or tissue is treated with the LPA RNAi agent, the expression of the gene (as measured by the level of RNA transcribed from the gene in the cell, cell population or tissue in which the LPA gene is transcribed, or the level of polypeptide, protein or protein subunit translated from mRNA) is reduced compared to the same cell, cell population or tissue before administration of the LPA RNAi agent.

[0266] In certain embodiments, the gene expression level and / or mRNA level of LPA in the subject to which the LPA RNAi agent is applied is reduced by at least about 5% or more, for example, 5% to 98%, relative to the subject before the LPA RNAi agent is applied or the subject who has not received the LPA RNAi agent. The gene expression level and / or mRNA level in the subject can be reduced in the cells, cell groups and / or tissues of the subject. In certain embodiments, the protein level of LPA in the subject to which the LPA RNAi agent is applied is reduced by more than 5%, for example, 5% to 98%, relative to the subject before the LPA RNAi agent is applied or the subject who has not received the LPA RNAi agent. The protein level in the subject can be reduced in the cells, cell groups, tissues, blood and / or other fluids of the subject. The reduction of gene expression, mRNA or protein levels can be assessed by any method known in the art. The reduction or decrease of LPA mRNA levels and / or protein levels is collectively referred to as the reduction or decrease of LPA in this application, or the inhibition or reduction of the expression of LPA.

[0267] Introducing into a cell when referring to an LPA RNAi agent means that the LPA RNAi agent is functionally delivered into a cell. Functional delivery means that the RNAi agent is delivered to the cell and has the intended biological activity (eg, sequence-specific inhibition of gene expression).

[0268] The present application is further described below through specific examples.

[0269] Example 1 Synthesis of Compound GENO-Gal-6

[0270] (1) Synthesis route

[0271]

[0272]

[0273] (2) Specific synthesis steps

[0274] 1) Preparation of compound Int-11-2

[0275]

[0276] Int-11-1 (10 g) was dissolved in (140 mL) DCM (Dichloromethane) and cooled to 0°C. TMSCN (Trimethylsilyl cyanide, trimethylsilyl cyanide (TMSCN)) (4.01 g) and BF3.Et2O (2.83 mL) were added dropwise and reacted for 10 min. The reaction was monitored by TLC plate (using Hexane:EtOAc = 5:1, KMnO4 for color development, raw material Rf = 0.3, α configuration Rf = 0.28, β configuration Rf = 0.27). The raw material reaction was complete. After the reaction was complete, 100 mL of saturated NaHCO3 aqueous solution was added to the reaction solution, and 100 ml of DCM was added to separate the organic phase. The organic phase was washed once with saturated brine, and the organic phase was concentrated, then dissolved in EtOAc (200 mL), washed once with NaHCO3 aqueous solution (100 mL), washed once with saturated brine, and the organic phase was dried over anhydrous sodium sulfate and concentrated. Then, it was purified by a normal silica gel column, and the polarity was slowly increased. When Hexane / EtOAc=20%, the α configuration was obtained, and when it was 25%, the β configuration was obtained. The α configuration obtained (5.3 g) of a white solid, and the β configuration obtained (3.7 g) of a colorless oil. 1 HNMR(400MHz,DMSO)δ6.03~6.06(dt,1H),5.91~5.94(dt,1H),5.35(dq,1H), 5.12(m,1H),4.30(dd,1H),4.30(dd,1H),3.82(ddd,1H),2.10~2.12(2s,6H).

[0277] 2) Preparation of compound Int-11-3

[0278]

[0279] Aqueous HCl solution (1M, 17.2 mL) was added to a suspension of Int-11-2 (3.7 g, β configuration, colorless oil) and 10% Pd / C (377 mg), and then added to a mixture of ethyl acetate / 2-propanol / ethanol (2:1:1, 90 mL in total), and stirred under hydrogen (40 Psi) for 48 hours. The reaction was monitored by TLC, the catalyst was removed by filtration through diatomaceous earth, and the solvent was concentrated under reduced pressure. The obtained crude product was washed twice with toluene, then dissolved in (10 mL methanol, 28% NH3.H2O (30 mL) was added, and stirred at room temperature for 16 hours. After the reaction solution was concentrated, it was washed three times with a 1:1 mixed solution of toluene and acetonitrile (50 mL). 1 g of the above crude product was dissolved in (40 mL) H2O and cooled to 0°C. NaHCO3 (1.4 g) and Na2CO3 (0.88 g) were added. FmocOSu (2.13 g) was dissolved in dioxane (40 mL) solvent, and then added dropwise to the above aqueous solution and reacted at room temperature for 1 hour. The reaction was monitored by TLC (DCM:MeOH=10:1, 254 nm, Rf=0.5). The product was purified by forward column, MeOH / DCM=5%, and Int-11-3 (340 mg) was obtained as a colorless solid. 1 H NMR(CDCl3): δ7.76-7.78(d,2H),7.58-7.60(d,2H),7.39-7.42(t,2H),7.30-7.34(t,2H),5.12(t,1H),4.42-4.52(m ,2H),4.22(t,1H),3.84(br.s,2H).3.47-3.57(m,3H),3.11-3.24(m,2H),1.30-1.56,1.67-1.72,2.05-2.22(m,4H).

[0280] 3) Preparation of compound Int-11-4

[0281]

[0282] Int-11-3 (340 mg) was dissolved in 2 ml of pyridine, cooled to 0°C, DMTrCl (450 mg) was dissolved in 2 ml of pyridine and added dropwise to the above solution, TLC monitoring showed that the raw material reacted completely. 5 ml of aqueous solution was added to quench the reaction, and the product int-11-4 (290 mg) was purified by reverse column C18 with MeCN / H2O=80%.

[0283] 4) Preparation of compound GENO-Int-11

[0284]

[0285] Int-11-4 (700 mg, 1.02 mmol) was dissolved in 2 mL of dichloromethane, and then DBU (310 mg, 2.04 mmol) was added to the above solution. After TLC monitoring, the reaction of the raw material was complete. 5 ml of saturated Na2CO3 solution was added to quench the reaction, and 20 mL of dichloromethane was used for extraction. The organic phase was concentrated and DCM:MeOH=10:1, (254 nm, Rf=0.5). The product was purified by forward column, MeOH / DCM=5%, and GENO-Int-11 (550 mg) was obtained as a yellow solid.

[0286] 5) Preparation of Compound Int-6-1

[0287]

[0288] Gal-3-5B (1.45 g, 3.24 mmol) was dissolved in anhydrous DMF (10 mL) solvent, and then HATU (1.64 g, 4.32 mmol), 3A molecular sieve (1 g) and DIEA (1.07 mL, 6.47 mmol) were added, and the reaction solution was stirred at room temperature for 30 min, and then GENO-int-11 (1 g, 2.16 mmol) was dissolved in DMF (10 mL) and added to the above reaction solution, and the reaction solution was stirred at room temperature overnight under argon protection. The reaction solution was filtered and purified by reverse column C18 MeCN / H2O=60% to obtain Int-6-1 (1.8 g). 1 H NMR: (400MHz, DMSO-d6) δ7.80 (d, J=9.2Hz, 1H), 7.71-7.73 (m, 1H), 7.39-7.41 (m, 2H), 7.24-7.30 (m, 6H), 7 .18-7.21(m,2H),6.87(d,J=8.8Hz,4H),5.21(d,J=3.6Hz,1H),4.95-4.98(m,1H),4.59(d,J=6.4Hz,1H),4 .47(d,J=8.4Hz,1H),4.00-4.05(m,2H),3.83-3.90(m,1H),3.64-3.73(m,7H),3.23-3.38(m,8H),2.97-3. 14(m,3H),2.04-2.14(m,5H),1.98(s,3H),1.89(s,3H),1.77(s,3H),1.64-4.66(m,1H)1.42-1.50(m,4H).

[0289] 5) Preparation of compound Geno-Gal-6

[0290]

[0291] Int-6-1 (2.1 g, 2.35 mmol) was dissolved in DCM (30 mL), Tetrazole (33 mg, 0.47 mmol), NMI (77.2 mg, 0.94 mmol) and 2 g molecular sieves were added, the reaction solution was replaced with argon three times, stirred at room temperature for 20 min, then the phosphorus reagent (920.81 mg, 3.06 mmol) was dissolved in a small amount of dichloromethane and added to the reaction solution, and stirred at room temperature for 1 hour. The reaction solution was washed twice with saturated NaHCO3 aqueous solution, once with water, and once with brine, concentrated at room temperature, and purified by reverse column C18 with MeCN / H2O=65% to obtain GENO-Gal-6 (1.5 g). 1 H NMR: (400MHz, CD3CN) δ7.48-7.50(m,2H),7.20-7.36(m,7H),6.83-6.87(m,4H),6.45-6.51(m, 1H),5.28(d,J=3.2Hz,1H),4.98-5.02(m,1H),4.49(d,J=8.4Hz,1H),3.90-4.12(m,4H),3.24- 3.76(m,20H),3.02-3.11(m,1H),2.49-2.59(m,1H),2.36-2.39(m,1H),2.08-2.25(m,9H),1.9 7(s,3H),1.91(s,3H),1.83(s,3H),1.71-1.74(m,1H),1.46-1.63(m,5H),0.85-1.39(m,20H).

[0292] 6) Preparation of compound Gal-5-1

[0293]

[0294] 1,12-Dodecanedioic acid monobenzyl ester (387 mg, 1.2 mmol) was dissolved in anhydrous DMF (N,N-Dimethylformamide) (10 mL) solvent, and then HBTU (O-Benzotriazole-N,N,N',N'-tetramethyl-uronium-hexafluorophosphate) (546 mg, 1.44 mmol), DIEA (N,N-Diisopropylethylamine) (0.65 mL, 3.6 mmol), HOBT (1-Hydroxybenzotriazole) (324 mg, 2.4 mmol) and GENO-Int-11 (560 mg, 1.2 mmol) were added, and then stirred at room temperature overnight under argon protection. The reaction solution was purified by reverse column C18 MeCN / H2O=70% to obtain the product Gal-5-1 (200 mg). 1 H NMR(400MHz,DMSO)δ7.68(t,1H),7.49-7.12(m,14H),6.86(d,4H),5.07(s,2H),4.58(d,1H),3.73(s,6H),3.38(dd,1H),3.28-3.16 (m,3H),3.22-2.85(m,3H),2.41-2.25(m,2H),2.11-2.00(m,2H),1.92(dd,1H),1.64(d,1H),1.57-1.41(m,4H),1.27-1.06(m,14H).

[0295] 7) Preparation of compound Gal-5-2

[0296]

[0297] Gal-5-1 (200 mg, 0.26 mmol) was dissolved in 5 mL of ethyl acetate, 50 mg of palladium carbon and triethylamine (0.11 mL, 0.78 mmol) were added, the reaction solution was stirred under hydrogen (15 psi) at room temperature for 16 hours, the reaction solution was filtered and concentrated to obtain Gal-5-2 (150 mg).

[0298] 8) Preparation of compound Gal-5-3

[0299]

[0300] Gal-5-2 (corresponding to formula I-1) (150 mg, 0.22 mmol) was dissolved in 5 mL of anhydrous DMF, and HBTU (101 mg, 0.27 mmol), DIEA (0.16 mL), 3A molecular sieves (1 g) and Gal-3-4C (441 mg. 0.22 mmol) were added to the solution. The mixture was then stirred at room temperature for 16 hours, and the reaction solution was purified by reverse column C18 with MeCN / H2O=60% to obtain the product Gal-5-3 (380 mg). 1 H NMR(400MHz,DMSO)δ7.91-7.67(m,10H),7.42(d,2H),7.34-7.24(m,6H),7.20(d,1H),6.99(s,1H),6 .87(d,4H),5.21(d,3H),4.97(dd,3H),4.60(s,1H),4.48(d,3H),4.09-3.95(m,10H),3.93-3.82(m, 3H),3.77-3.66(m,9H),3.61-3.48(m,12H),3.45-3.20(m,16H),3.09-2.95(m,15H),2.27(t,6H),2. 10(s,9H),2.05(dd,10H),1.99(s,9H),1.89(s,9H),1.76(d,9H),1.63-1.38(m,24H),1.16(s,14H).

[0301] 9) Preparation of compound Gal-5-4

[0302]

[0303] Gal-5-3 (370 mg, 0.15 mmol), succinic anhydride (75 mg, 0.76 mmol), 3A molecular sieves (0.5 g) and DMAP (4-Dimethylaminopyridine) (46 mg, 0.38 mmol) were dissolved in 5 mL THF (Tetrahydrofuran), and then the reaction solution was stirred at 40°C overnight. The reaction solution was purified by reverse column C18 with MeCN / H2O = 40% to obtain the product Gal-5-4 (220 mg).

[0304] 10) Synthesis of GENO-Gal-5, an aminogalactose compound attached to a solid support

[0305]

[0306] Gal-5-4 (220 mg, 0.086 mmol) was suspended in 4 ml CH3CN and 2 ml DMF, DIEA (0.035 mL, 0.216 mmol) and HBTU (49.07 mg, 0.129 mmol) were added dropwise, and the mixture was stirred at room temperature for 5 minutes. Aminomethyl resin (99.51 mg, 100-200 mesh, amino loading 250 umol / g) was added to the reaction solution, and the reaction was carried out on a shaking table at 25°C at a speed of 220 rpm. After the reaction for 16 h, the filter cake was filtered and washed with DCM 3 times, 30 ml each time, acetonitrile 3 times, 30 ml each time, and 40 ml of water for 3 hours. 0ml n-hexane was eluted 3 times, vacuum oil pump was dried for 2h, and then mixed reagent (CapB1, 4-dimethylaminopyridine, N-methylimidazole and acetonitrile, 11.2mL / 12.4mg / 0.50mL / 4.32mL) was added for capping reaction. The mixture was placed on a shaker at 25°C, with a speed of 220 rpm, and reacted for 16h. The reaction liquid was filtered, and the filter cake was eluted with acetonitrile 3 times, 30ml each time, and filtered to dryness. The target product, GNEO-Gal-5 compound 160mg, was obtained by drying under reduced pressure of a vacuum oil pump overnight.

[0307] Example 2 Synthesis of siRNA

[0308] Unmodified siRNA was provided by WuXi AppTec (sequence in Table 1). The synthesis process of modified siRNA (see Tables 2 and 3) is briefly described as follows: On a Dr.Oligo 48 synthesizer (Biolytic), starting with the Universal CPG vector, nucleoside phosphoramidite monomers were connected one by one according to the synthesis procedure, where 2'-F RNA, 2'-O-methyl RNA and other nucleoside phosphoramidite monomer raw materials were purchased from Wuhu Huaren and Shanghai Zhaowei. 5-Ethylthio-1H-tetrazole (ETT) was used as an activator (0.6M acetonitrile solution), 0.22M PADS was dissolved in a 1:1 volume ratio of acetonitrile and trimethylpyridine (Shanghai Lingjiang) mixed solvent, the resulting solution was used as a sulfurizing agent, and iodine pyridine / water solution (Shanghai Lingjiang) was used as an oxidant.

[0309] In oligonucleotides, nucleotide monomers are linked to each other through 5'-3'-phosphodiester bonds, including phosphorothioate bonds and phosphodiester bonds.

[0310] After solid phase synthesis, the oligoribonucleotide was cleaved from the solid support and soaked in a 3:1 28% ammonia and ethanol solution at 50°C for 15 hours. Then centrifuged, the supernatant was transferred to another centrifuge tube, concentrated and evaporated to dryness, and purified by C18 reverse chromatography, with a mobile phase of 0.1M TEAA and acetonitrile, and DMTr was removed using a 3% trifluoroacetic acid solution. The target oligonucleotide was collected and freeze-dried, and identified as the target product by LC-MS, and then quantified by UV (260nm).

[0311] The obtained single-stranded oligonucleotides are annealed according to the complementary pairing in an equal molar ratio, and the double-stranded siRNA obtained is finally dissolved in 1×PBS or sterile water and adjusted to the required concentration for the experiment.

[0312] In the sequences of Table 1, Table 2 and Table 3, each symbol is used to represent the following modified nucleotides (esters):

[0313] A = adenosine-3'-phosphate

[0314] C = cytidine-3'-phosphate

[0315] G = guanosine-3'-phosphate

[0316] U = Uridine-3'-phosphate

[0317] Am = 2'-O-methyladenosine-3'-phosphate

[0318] Ams = 2'-O-methyladenosine-3'-phosphorothioate

[0319] Cm=2'-O-methylcytidine-3'-phosphate

[0320] Cms = 2'-O-methylcytidine-3'-phosphorothioate

[0321] Gm=2'-O-methylguanosine-3'-phosphate

[0322] Gms = 2'-O-methylguanosine-3'-phosphorothioate

[0323] Um = 2'-O-methyluridine-3'-phosphate

[0324] Ums = 2'-O-methyluridine-3'-phosphorothioate

[0325] Af = 2'-fluoroadenosine-3'-phosphate

[0326] Afs = 2'-fluoroadenosine-3'-phosphorothioate

[0327] Cf = 2'-fluorocytidine-3'-phosphate

[0328] Cfs = 2'-fluorocytidine-3'-phosphorothioate

[0329] Gf = 2'-fluoroguanosine-3'-phosphate

[0330] Gfs = 2'-fluoroguanosine-3'-phosphorothioate

[0331] Uf = 2'-fluorouridine-3'-phosphate

[0332] Ufs = 2'-fluorouridine-3'-phosphorothioate

[0333] Wherein: the lowercase letter m indicates that the nucleotide adjacent to the left of the letter m is a methoxy-modified nucleotide; the lowercase letter f indicates that the nucleotide adjacent to the left of the letter f is a fluorine-modified nucleotide;

[0334] When a lowercase letter s is in the middle of a capital letter, it means that the connection between the two nucleotides adjacent to the letter s is a phosphorothioate connection;

[0335] When the lowercase letter s is the first at the 3' end, it means that the nucleotide terminal adjacent to the left side of the letter s is a phosphorothioate group;

[0336] Table 1 Unmodified siRNA numbers and sequences targeting human LPAmRNA

[0337]

[0338]

[0339]

[0340]

[0341]

[0342] Table 2 Modified siRNA numbers and sequences targeting human LPAmRNA

[0343]

[0344]

[0345]

[0346]

[0347]

[0348]

[0349]

[0350]

[0351]

[0352]

[0353]

[0354] Table 3 Numbers and sequences of modified siRNAs targeting human LPA mRNA conjugated with ligands

[0355]

[0356]

[0357]

[0358] The unmodified sequence of the above-mentioned Geno-1-1002M is: AUAACUCUGUCCAUUACCG (SEQ ID No. 184); the corresponding unmodified sequence of the sense strand is: CGGUAAUGGACAGAGUUAU (SEQ ID No. 188). The unmodified sequence of the above-mentioned Geno-1-1003M is: UCGUAUAACAAUAAGGGGCUG (SEQ ID No. 185); the corresponding unmodified sequence of the sense strand is: CAGCCCCUUAUUGUUAUACGA (SEQ ID No. 189). The unmodified sequence of the above-mentioned Geno-1-1004M is: AUAACUCUGUCCAUUACCG (SEQ ID No. 186); the corresponding unmodified sequence of the sense strand is: CGGUAAUGGACAGAGUUAU (SEQ ID No. 189).

[0359] [Gal-5]Structural formula:

[0360]

[0361] Gal-6 is the abbreviation of the target product Geno-Gal-6 prepared in step 5) of Example 1;

[0362] [Gal-6]s[Gal-6]s[Gal-6]Structural formula:

[0363]

[0364] [ST23sST23sST23sC6XLT]Structural formula:

[0365]

[0366] Example 3 In vitro experiments of LPA RNAi agents

[0367] We synthesized 91 computationally identified potential LPA RNAi agents (Table 1) and screened them for in vitro efficacy.

[0368] For screening purposes, human LPAc DNA sequence (accession number NM_005577.1) or its fragment is subcloned from commercially available mammalian expression vector (Origene) to commercially available screening plasmid psiCHECK2 (Promega) based on reporter, producing Renilla luciferase / LPA fusion mRNA. For LPA RNAi agent efficacy in human background, Huh7 cells (human hepatocellular carcinoma system) are plated in 96-well format with about 10,000 cells / well. Each LPA RNAi agent is co-transfected with 25ng psiCHECK2-LPA plasmid DNA per well and 0.2 μL LipoFectamine 2000 per well with two concentrations (1nM and 0.1nM). Gene knockdown is determined by measuring the Renilla luciferase level normalized to the level of the constitutively expressed firefly luciferase also present on the psiCHECK2 plasmid using dual luciferase reporter assay (Promega). (Table 4)

[0369] As shown in Table 4, 66 sequences among the 91 sequences showed a knockdown efficiency greater than 60% at 1 nM; and 61 sequences showed a knockdown efficiency greater than 50% at 0.1 nM.

[0370] Table 4. In vitro efficacy screening results of LPA RNAi agents determined by dual luciferase reporter assay

[0371]

[0372]

[0373]

[0374] Example 4 LPA RNAi agent EC50 determination

[0375] A seven-point EC50 curve was generated using the same cells and transfection conditions as in Example 3, with LPA RNAi agent concentrations ranging from 0.1 fM to 10 M. EC50 values ​​were determined by fitting the dose response curve using "Sigmoidal Dose Response (Variable Slope)" in GraphPad Prism (Table 5).

[0376] As shown in Table 5, the EC50 values ​​of the tested compounds ranged from 1 pM to 60 pM.

[0377] Table 5. EC50 values ​​(pM) of the indicated LPA RNAi agents determined in vitro

[0378]

[0379]

[0380] Example 5 Analysis of in vitro test results of modified LPA RNAi agents

[0381] The sequences selected by the preliminary screening were modified and each LPA RNAi agent was co-transfected at a concentration of 1 nM with 25 ng of psiCHECK2-LPA plasmid DNA per well and 0.2 μL of LipoFectamine 2000 per well using the same cells and transfection conditions as in Example 3. Gene knockdown was determined by measuring the level of Renilla luciferase normalized to the level of constitutively expressed firefly luciferase also present on the psiCHECK2 plasmid using a dual luciferase reporter assay (Promega, Madison, WI) (Table 6).

[0382] As shown in Table 6, 41 out of 71 sequences showed a knockdown efficiency greater than 60%.

[0383] Table 6. In vitro efficacy screening results of LPA RNAi agents determined by dual luciferase reporter assay

[0384]

[0385]

[0386] Example 6 Screening of non-conjugated LPA RNAi agents by inhibiting LPA mRNA expression in human RT-4 cells

[0387] Each LPA RNAi agent was incubated with 0.4 μL RNAiMax (Invitrogen) at a concentration of 50 nM. RT-4 cells (human bladder transitional cell papilloma cell line) were plated in 24-well plates at approximately 70,000 cells / well and inoculated on the incubated transfection complex. 24 hours after transfection, total RNA was extracted using RNeasy 96 kits (Qiagen). Using Novizan cDNA reverse transcription kit and qPCR kit, cDNA synthesis and real-time PCR detection were performed relative to the GAPDH mRNA expression as a housekeeping transcript in the corresponding samples, and LPA mRNA levels were determined by qRT-PCR (Table 7).

[0388] Table 7. In vitro efficacy screening results of LPA RNAi agents determined by qRT-PCR assay

[0389]

[0390] Example 7 Distribution ratio of conjugated LPA RNAi agent in the liver and kidney of wild-type mice after subcutaneous administration

[0391] 30 C57BL6 / J mice were divided into 10 groups, and the designated 5 groups of LPA RNAi agents were subcutaneously injected into each group of mice at a dose of 10 mg / kg on the first day. Tissues were collected from 5 groups of mice 1 hour after administration, and tissues were collected from the other 5 groups of mice 24 hours after administration. The collected tissue samples were quickly frozen and transferred to -80°C for storage. After tissue homogenization, the concentration of the corresponding LPA RNAi agent in the liver tissue homogenate and the kidney tissue homogenate was measured by hybridization fluorescent probe-enzyme-linked immunosorbent assay, and the liver-kidney ratio was calculated by dividing the liver tissue homogenate concentration by the kidney tissue homogenate concentration for evaluation. The results are shown in Table 8.

[0392] Figure 2 The ratio of compound concentrations in the liver and kidney of wild-type mice after SC administration of 10 mg / kg LPARNAi agent is shown. The results show that the concentrations of Geno-1-105M to Geno-1-108M in the targeted organ liver are much higher than those in the non-targeted organ kidney at different time points, and the ratio of drug concentrations in the liver to the kidney is much greater than 1. At the same time, the concentration of Geno-1-1004M in the non-targeted organ kidney is greater than that in the liver at the two time points tested, and the ratio of drug concentrations in the liver to the kidney is less than 1.

[0393] Table 8 Ratio of compound concentrations in liver and kidney of wild-type mice after SC administration of 10 mg / kg LPA RNAi agent

[0394]

[0395] Example 8 In vivo testing of the efficacy of LPA RNAi agents in C57 transiently transgenic mice

[0396] Two weeks before the administration of LPA RNAi agent, wild-type mice (male, C57 BL / 6) were injected with plasmids containing SEAP gene under the control of mouse albumin promoter (the plasmids contain human LPA gene target sequence clones) by tail vein hyperbaric injection. These mice are called SEAP-LPA-HDI mice. On day 0, SEAP-LPA-HDI mice were subcutaneously injected with 1mg / Kg or 3mg / Kg of LPA RNAi Geno-1-1001M or Geno-1-1002M solution, with a dosing volume of 5ml / Kg, and control mice were given an equal volume of phosphate buffered saline (PBS). Mouse serum was collected 14 days before administration (Day-14), on the day of administration (Day0), and on days 7, 14, 21, 28, and 35 after administration (only Geno-1-1001M group was collected from days 21 to 35).

[0397] LPA expression knockdown was evaluated by detecting SEAP protein levels in mouse serum using the chemiluminescent reporter system Phospha-LightTM (Life Technologies). For normalization, the SEAP level of each animal at a given time point was divided by the pretreatment level in this animal to determine the ratio of "normalized to pretreatment" expression; then the expression at a specific time point was normalized to the control group by dividing the "normalized to pretreatment" ratio of each animal by the average "normalized to pretreatment" ratio of all mice in the control group. This normalizes the expression at each time point to the expression of the control group.

[0398] Figure 3 The detection results of this embodiment are shown.

[0399] The conjugated LPA RNAi agent was administered to SEAP-LPA-HDI mice as described above. Each mouse received a single subcutaneous injection (SC) of 1 mg / kg or 3 mg / kg LPA RNAi agent Geno-1-1001M or Geno-1-1002M solution, and the SEAP protein level in the serum was monitored for up to 35 days. The knockdown level and response duration are shown in Table 9. The 1 mg / kg and 3 mg / kg LPA RNAi agent Geno-1-1002M showed a maximum knockdown of SEAP protein levels of ≥57% and ≥67% on the seventh day after administration. The SEAP protein level had returned to the control group level on the 14th day after administration, and no knockdown effect was shown. The 1 mg / kg and 3 mg / kg LPA RNAi agent Geno-1-1001M showed a maximum knockdown of SEAP protein levels of ≥87% and ≥57% on the seventh day after administration, and the 3 mg / kg LPA RNAi agent Geno-1-1001M showed a knockdown of SEAP protein levels of ≥72% until day 35. The knockdown effect and knockdown duration of the LPA RNAi agent Geno-1-1001M on SEAP protein levels at the same dose were significantly better than those of the LPA RNAi agent Geno-1-1002M.

[0400] Table 9 Relative Apo(a) levels in mouse serum after subcutaneous administration of different doses of conjugated LPA RNAi agents

[0401]

[0402] Example 9 In vivo testing of the efficacy of LPA RNAi agents in NOD SCID transiently transgenic mice

[0403] Ten days before the administration of LPA RNAi agents, NOD SCID mice (male) were injected with minicircle DNA (MC hLPA) containing human LPA gene target sequence clones by tail vein hyperbaric injection. These mice are referred to as MC hLPA HDI mice. On day 0, these mice were subcutaneously injected with 0.3 mg / Kg, 1 mg / Kg, 3 mg / Kg or 9 mg / kg LPA RNAi agent (Geno-1-107M, Geno-1-1003M and Geno-1-1004M) solution, with a dosing volume of 5 ml / Kg, and control mice were given an equal volume of phosphate buffered saline (PBS). Mouse serum was collected 3 days before administration (Day-3), on the day of administration (Day0), and on days 4, 7, 14, 21, 28 and 35 after administration.

[0404] LPA expression knockdown was evaluated by measuring Apo(a) protein levels in mouse serum using an ELISA method (Apo(a), Abcam). For normalization, the Apo(a) level of each animal at a given time point was divided by the pretreatment level (Day0) in this animal to determine the ratio of "normalized to pretreatment" expression; then the expression at a specific time point was normalized to the control group by dividing the "normalized to pretreatment" ratio of each animal by the average "normalized to pretreatment" ratio of all mice in the control group. This normalized the expression at each time point to the expression of the control group.

[0405] Figure 4 The detection results of this embodiment are shown.

[0406] The conjugated LPA RNAi agent was administered to MC hLPA HDI mice as described above. Each mouse received a single subcutaneous injection (SC) of 0.3 mg / Kg, 1 mg / Kg, 3 mg / Kg or 9 mg / kg LPA RNAi agent (Geno-1-107M, Geno-1-1003M and Geno-1-1004M) solution, and the Apo (a) protein level in the serum was monitored for up to 35 days. The knockdown level and response duration are shown in Table 10. The maximum knockdown of Apo (a) protein levels was shown on the 7th day after administration of 0.3 mg / Kg, 1 mg / Kg or 3 mg / Kg LPA RNAi agent (Geno-1-1004M) solution, and the knockdown reached 33%, 58% and 79%, respectively. On the 28th day after administration, 0.3mg / Kg, 1mg / Kg or 3mg / Kg LPARNAi agent (Geno-1-1004M) knocked down Apo(a) protein levels by 20%, 42% and 45%, respectively. 3mg / Kg LPARNAi agent (Geno-1-1004M) showed a knockdown of ≥20% of Apo(a) protein levels until the 35th day after administration. 1mg / Kg or 3mg / Kg LPARNAi agent (Geno-1-1003M) solution showed the maximum knockdown of Apo(a) protein levels on the 7th day after administration, with a knockdown of 79% and 92%, respectively. On the 28th day after administration, 1mg / Kg or 3mg / Kg LPARNAi agent (Geno-1-1003M) knocked down Apo(a) protein levels by 52% and 90%, respectively. 3mg / Kg LPA RNAi agent (Geno-1-1003M) was administered until day 35 and showed a knockdown of ≥83% on Apo(a) protein levels. 0.3mg / Kg, 1mg / Kg, 3mg / Kg or 9mg / kg LPA RNAi (Geno-1-107M) solution showed the maximum knockdown of Apo(a) protein levels on day 7 after administration, with knockdowns of 45%, 71%, 96% and 99%, respectively. On day 28 after administration, 0.3mg / Kg, 1mg / Kg, 3mg / Kg or 9mg / kg LPA RNAi agent (Geno-1-107M) knocked down Apo(a) protein levels by 33%, 45%, 88% and 98%, respectively. And 3mg / kg LPA RNAi agent Geno-1-107M was administered until day 35 and showed a knockdown of ≥74% on Apo(a) protein levels. The 9 mg / kg LPA RNAi agent Geno-1-107M also showed ≥97% knockdown of Apo(a) protein levels until day 35 after administration.After administration of the same dose of 3 mg / kg LPA RNAi agent, at the same time point, the knockdown effect of Geno-1-107M on Apo(a) protein levels was significantly better than that of Geno-1-1004M, and was comparable to that of Geno-1-1003M.

[0407] Table 10 Relative Apo(a) levels in mouse serum after subcutaneous administration of different doses of conjugated LPA RNAi agents

[0408]

[0409] Example 10 In vivo testing of the efficacy of LPA RNAi agents in NOD SCID transiently transgenic mice (single dose)

[0410] Ten days before the LPA RNAi agent was administered, a mini-circle DNA (MC hLPA) containing a cloned LPA gene target sequence was injected into NOD SCID mice (male) by high-pressure injection in the tail vein. These mice are referred to as MC hLPA HDI mice. On day 0, these mice were subcutaneously injected with a 1 mg / Kg LPA RNAi agent test solution, with a dosing volume of 5 ml / Kg, and mice in the control group were given an equal volume of phosphate buffered saline (PBS). Mouse serum was collected 3 days before administration (Day-3), on the day of administration (Day0), and on the 4th, 7th, 14th, 21st, and 28th days after administration (only some groups collected samples on days 21 and 28).

[0411] LPA expression knockdown was evaluated by measuring Apo(a) protein levels in mouse serum using an ELISA method (Apo(a), Abcam). For normalization, the Apo(a) level of each animal at a given time point was divided by the pretreatment level (Day0) in this animal to determine the ratio of "normalized to pretreatment" expression; then the expression at a specific time point was normalized to the control group by dividing the "normalized to pretreatment" ratio of each animal by the average "normalized to pretreatment" ratio of all mice in the control group. This normalized the expression at each time point to the expression of the control group.

[0412] Figure 5 The detection results of this embodiment are shown.

[0413] The conjugated LPARNAi agent was administered to MC hLPAHDI mice as described above. Each mouse received a single subcutaneous injection (SC) of 1 mg / Kg LPARNAi agent solution, and the Apo (a) protein level in the serum was monitored for up to 28 days. The knockdown level and response duration are shown in Table 11. On the 7th day of administration, 10 LPARNAi agents administered at 1 mg / Kg showed a knockdown of greater than 50%; 3 of the LPARNAi agents administered at 1 mg / Kg showed a knockdown of greater than 70%; one of the Geno-1-107M knocked down the Apo (a) protein level by greater than 84%. On the 14th day of administration, 8 LPA RNAi agents 1 mg / Kg administered showed a knockdown of more than 50%, of which 1 LPA RNAi agent Geno-1-112M 1 mg / Kg administered showed a knockdown of more than 70%; 2 LPA RNAi agents Geno-1-107M and Geno-1-1003M administered had a knockdown of Apo (a) protein levels of more than 80%. On the 28th day of administration, 2 LPA RNAi agents Geno-1-107M and Geo-1-111M administered still maintained a knockdown of 65% and 54% on Apo (a) protein levels.

[0414] Table 11 Relative Apo(a) levels in mouse serum after subcutaneous administration of conjugated LPA RNAi agent 1 mg / Kg

[0415]

[0416] Example 11 In vivo testing of the efficacy of LPA RNAi agents in NOD SCID transiently transgenic mice

[0417] 27 days before LPA RNAi administration, NOD SCID mice (male) were injected with minicircle DNA (MC hLPA) containing LPA gene target sequence clones by tail vein high pressure injection. These mice are called MC hLPA HDI mice. On day 0, these mice were subcutaneously injected with 1 mg / Kg LPA RNAi test solution, and the administration volume was 5 ml / Kg. The control group mice were given an equal volume of phosphate buffered saline (PBS). Mouse serum was collected 3 days before administration (Day-3), on the day of administration (Day0), and on the 4th day, 11th day and 18th day after administration.

[0418] LPA expression knockdown was evaluated by measuring Apo(a) protein levels in mouse serum using an ELISA method (Apo(a), Abcam). For normalization, the Apo(a) level of each animal at a given time point was divided by the pretreatment level (Day0) in this animal to determine the ratio of "normalized to pretreatment" expression; then the expression at a specific time point was normalized to the control group by dividing the "normalized to pretreatment" ratio of each animal by the average "normalized to pretreatment" ratio of all mice in the control group. This normalized the expression at each time point to the expression of the control group.

[0419] Figure 6 The detection results of this embodiment are shown.

[0420] Gal-6 conjugated LPA RNAi agents were administered to MC hLPA HDI mice as described above. Each mouse received a single subcutaneous injection (SC) of 1 mg / Kg LPA RNAi agent solution, and the Apo (a) protein level in serum was monitored for 18 days. The knockdown level and response duration are shown in Table 12. On the 4th day of application, LPA RNAi agents Geno-1-107M and Geno-1-120M 1mg / Kg showed 69% and 66% knockdown; on the 11th day of application, LPA RNAi agents Geno-1-107M and Geno-1-120M 1mg / Kg showed 70% and 73% knockdown. On the 18th day of application, LPA RNAi agents Geno-1-107M and Geno-1-1003M 1mg / Kg showed 64% and 56% knockdown.

[0421] Table 12 Relative Apo(a) levels in mouse serum after subcutaneous administration of Gal-6-conjugated LPA RNAi agent 1 mg / Kg

[0422]

[0423] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions and improvements made within the principles of the present invention should be included in the protection scope of the present invention.

Claims

1. An RNA interference agent of LPA, comprising a first nucleotide sequence, wherein the first nucleotide sequence consists of the following sequence: The antisense strand is SEQ ID No.10 and the sense strand is SEQ ID No.101; or the antisense strand is SEQ ID No.17 and the sense strand is SEQ ID No.

108.

2. The RNA interfering agent according to claim 1, characterized in that The first nucleotide sequence is shown in the following table Any set of AS chains and SS chains: In the following sequence, each symbol is used to represent the following modifications: Am = 2'-O-methyladenosine-3'-phosphate Ams = 2'-O-methyladenosine-3'-phosphorothioate Cm=2'-O-methylcytidine-3'-phosphate Cms = 2'-O-methylcytidine-3'-phosphorothioate Gm=2'-O-methylguanosine-3'-phosphate Gms = 2'-O-methylguanosine-3'-phosphorothioate Um = 2'-O-methyluridine-3'-phosphate Ums = 2'-O-methyluridine-3'-phosphorothioate Af = 2'-fluoroadenosine-3'-phosphate Afs = 2'-fluoroadenosine-3'-phosphorothioate Cf = 2'-fluorocytidine-3'-phosphate Gf = 2'-fluoroguanosine-3'-phosphate Uf = 2'-fluorouridine-3'-phosphate Ufs = 2'-fluorouridine-3'-phosphorothioate VP = vinyl phosphonate, 3. The RNA interfering agent according to claim 1 or 2, wherein the RNA interfering agent further comprises a conjugated ligand, wherein the conjugated ligand comprises at least one of the following chemical formulas: Where Y is O or S; X is a nucleotide sequence.

4. The RNA interfering agent according to claim 3, characterized in that The conjugated ligand is conjugated to the 5' end and / or the 3' end of the sense strand.

5. The RNA interfering agent according to claim 3, characterized in that: The first nucleotide sequence is: 359AS: AmsUfsAmAmCfUmCmUmGm UmCmCm AmUfUm AfCmCm AmUmGms GmsUm, and 370SS: CmsAmsUmGmGmUm AmAmUf GfGfAm CmAmGm AmGmUm UmAmUms[Gal-6]s[Gal-6]s[Gal-6]; or 498AS: AmsAfsGmAmUfUmGmAmCmAmUmGmUmCfCmUfUmCmCmUmGmsUmsGm, and 511SS: CmsAmsGmGmAmAmGmGmAfCfAfUmGmUmCm AmAmUm CmUmUms[Gal-6]s[Gal-6]s[Gal-6], wherein the structural formula of [Gal-6]s[Gal-6]s[Gal-6] is:

6. The use of an RNA interfering agent according to any one of claims 1-5 for preparing a medicament, wherein the medicament is used to prevent and / or treat cardiovascular and cerebrovascular diseases, wherein the cardiovascular and cerebrovascular diseases include hyperlipidemia, stroke, coronary heart disease and myocardial infarction.

7. The use according to claim 6, characterized in that The drug is used to reduce LPA mRNA or protein expression in mammals, and the expression level of the LPA protein is 34.100 nmol / L or above.

8. The use according to claim 6, wherein the medicament comprises a pharmaceutically acceptable excipient.

9. The use according to claim 8, characterized in that The pharmaceutically acceptable excipient is PBS buffer or physiological saline.

10. The use according to claim 6, characterized in that The medicine is a composition and further comprises at least one of LDL-C, cholesterol and triglyceride lowering agents.

11. The use according to claim 6, characterized in that: The drug is a composition and also includes PCSK9 RNAi inhibitors, PCSK9 antibody inhibitors and PCSK9 small molecule inhibitors.